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Non-insulin dependent diabetes mellitus (NIDDM) is often associated with 
hyperinsulinemia and insulin resistance. Since there is little information about 
cardiovascular abnormalities in NIDDM, this study was conducted to evaluate 
the potential role of insulin resistance in two new animal models of insulin 
resistance, the young Zucker Diabetic Fatty (ZDF) and the Hybrid Zucker 
Diabetic Fatty/Spontaneously Hypertensive Heart Model (ZDF/SHHF). To 
evaluate the potential role of insulin resistance in cardiovascular abnormalities, 
the thiazolidinedione, pioglitazone (10 mg/kg/day p.o.), was used. This drug 
significantly decreased plasma insulin, glucose, triglycerides and cholesterol in 
young and hybrid diabetic rats.
Pioglitazone improved the insulin resistance in the two NIDDM models. 
Concurrently, there was impaired cardiac performance in young ZDF diabetic 
rats relative to non-diabetic rats; however, there was no impaired cardiac 
performance in untreated diabetic rats relative to untreated non-diabetic rats as 
seen in IDDM models. Pioglitazone also significantly increased body weights 
and heart weights, a potentially detrimental occurrence in the NIDDM rats. The 
increased heart weights seen in the pioglitazone treated diabetic rats may be 
responsible for the impaired cardiac performance at the lower end of the 
preload scale. Pioglitazone was able to decrease blood pressure in young 
hybrid diabetic rats relative to non-diabetic rats even though this diabetic rat 
model did not show elevated diabetic blood pressures. C orrecting 
hyperinsulinemia with pioglitazone may be responsible for this drug's effects 
observed in the young ZDF and young hybrid ZDF/SHHF rats.
Vanadyl sulfate (0.75 mg/ml) resulted in decreased plasma glucose and 
triglycerides in young hybrid ZDF/SHHF diabetic rats without lowering plasma 
insulin or modifying cardiovascular parameters. Vanadyl sulfate also lowered 
plasma glucose without affecting plasma triglycerides and cholesterol in the 
IDDM model (older ZDF).
Hydralazine (5 mg/kg b i d.) did not significantly affect hyperinsulinémie young 
hybrid ZDF/SHHF rats except to decrease body weights increase heart weight 
to body weight ratios, and decreased total cholesterol and HDL cholesterol 
ratios. Hydralazine improved the rate of relaxation in hybrid ZDF/SHHF diabetic 
rats.
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1 .0  IN TR O D U C TIO N
Diabetes m ellitus, hypertension, hyperllp idem ia, and hyperinsu linem ia  
separately are believed to have deleterious effects on the heart. Together, 
diabetes, hypertension and hyperlip idem ia have been shown to have 
cumulative deleterious effects in insulin-dependent diabetes mellitus (IDDM) as 
measured in the working heart model. This effect was also seen in conscious 
deoxycorticosterone treated hypertensive diabetic rats (Schenk and McNeill, 
1991). In non-insulin dependent diabetic (NIDDM) patients, many or all of these 
phenomena may be present and it is speculated that hyperinsulinem ia or 
insulin resistance may be associated with one or more of these clinical aspects. 
The overall purpose of this study was to examine the potential role of insulin 
resistance (a key factor of NIDDM) in the development of hypertension or other 
cardiovascular complications of diabetes.
Several animal models of NIDDM involving insulin resistance have recently 
been developed. These animals have in common the fact that they are obese 
and have elevated lipids. The purpose of this study was to evaluate whether or 
not drugs capable of reducing insulin resistance have the potential to reduce 
cardiovascular complications of diabetes. Three drugs (pioglitazone, vanadyl 
and hydralazine) were evaluated in two animal models of NIDDM. The Zucker 
diabetic fatty (ZDF) rat was selected as the first NIDDM-insulin resistant model. 
In the early stages of these animals' lives, they are hyperinsulinémie, insulin 
resistant, hypertriglyceridemic and hyperglycemic, closely resembling human 
NIDDM. At a later stage in these rats' development, they become 
hypoinsulinemic and more accurately resemble IDDM. These animals remain 
hyperglycemic and hypertriglyceridemic whether in the hyperinsulinémie phase
1
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or in the hypoinsulinemic phase. The second animal model used was a hybrid 
rat model. These ZDF-SHHF hybrid rats are a cross between the non­
hypertensive Zucker diabetic fatty (ZDF/Drt-fa) rat and the hypertensive 
S H H F / M c c - c p  rat. The hybrid rats are obese, insu lin -res is tan t, 
hypertriglyceridemic and a good rat model of NIDDM. Using their lean litter 
mates as controls, the three drugs were used to evaluate their ability to improve 
the diabetic and cardiovascular state.
I.1 Diabetes Mellitus
Diabetes is one of the world's most common diseases. There are several forms 
of diabetes mellitus, including: type I, which is insulin-dependent (IDDM); type
II, which is non-insulin-dependent (NIDDM); and gestational diabetes. 
Gestational diabetes is observed as impaired glucose to lerance during 
pregnancy (Brisco, 1993).
Characteristically, IDDM patients are usually not overweight, are variably aged, 
have a rapid onset of the disease and require insulin therapy to stay alive. 
Characteristics shared among IDDM and NIDDM include hyperglycem ia, 
polyuria, polydipsia and polyphagia. Most diabetics, if not properly controlled, 
also exhibit hyperlipidemia. Patients with IDDM release inadequate pancreatic 
insulin. Insulin is produced and secreted by |3 (beta) cells In the Islets of 
Langerhans. it is believed that IDDM occurs as a result of an autoimmune 
attack on these islet cells resulting in the destruction of p cells. In this scenario, 
autoreactive T lymphocytes initiate and oversee p cell specific immune 
destruction (Eisenberth, 1986).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The key to treating this type o f diabetes mellitus is insulin therapy. Insulin 
comes in many formulations and preparations. Patients self-monitor their blood 
glucose and administer their insulin subcutaneously on a daily basis. IDDM 
accounts for approximately 5 to 10 percent of all diabetic patients in the United 
States (ADA, 1991). Recently, a strong association between IDDM and certain 
genetic markers (HLA DR3 and DR4) has been found; however, to date, most 
individuals with these genetic markers do not develop diabetes. This makes 
predicting those who might become diabetic difficult. Some studies are being 
conducted to look at treating potential diabetics, based on presence of these 
genetic markers, or insulin antibodies with immunosuppressants such as 
cyclosporine and azathioprine to prevent or delay the onset of the disease.
NIDDM, on the other hand, is characterized by obesity (usually), hyperglycemia 
and insulin resistance (decreased tissue sensitivity or responsiveness to 
insulin). This form of diabetes mellitus accounts for 90 to 95 percent of the 
diabetics in the United States, approximately 12 million cases. Patients with 
NIDDM have a functioning pancreas and produce some insulin, but it is either 
insufficient in quantity or ineffective at the tissue level. This form of the disease 
can be asymptomatic for many years, has a slow progression, and is usually 
inherited.
The 1991 Diabetes Vital Statistics handbook lists several major risk factors for 
NIDDM: a family history of diabetes; obesity (body weight, due to fat, above 
20% ideal); race (Native American, Hispanic or African American); age older 
than 40; previous identification of impaired glucose tolerance; hypertension or 
significant hyperlipidemia; and a history of gestational diabetes mellitus or 
delivery of a baby over 9 pounds. Of these risk factors, obesity is the most
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Important. A 3-fold higher incidence of NIDDM occurs in patients 40 % above 
desirable weight compared to patients of normal body weight (ADA, 1991). 
There are many drug therapies for NIDDM. For details see section 1.5.
1.2 Complications
There are many complications of diabetes mellitus, both acute and chronic. 
C hron ic com p lica tions include ca rd iovascu la r d isease, re tinopa thy, 
nephropathy and neuropathy. Acute com plica tions include d iabetic  
ketoacidosis, hyperglycemic coma, and infections. Hypoglycemic episodes due 
to overdoses of insulin or oral hypoglycemics are another complication.
Cardiovascular disease (CVD) is a term used to describe a group of diseases 
that affect the heart and blood vessels. Diseases in this group include strokes, 
ischem ic heart diseases such as angina and coronary artery disease 
(atherosclerosis), peripheral vascular disease, ventricu la r hypertrophy, 
cardiomyopathy and heart failure. CVD is tremendously more likely in diabetic 
patients than the general population. In the United States, diabetics are 2-4 
times more prone to die from heart disease than the non-diabetic population. 
Evidence of coronary heart disease is present in 7.5 to 16.6 percent of diabetics 
older than 45 years of age (ADA, 1991). Within the diabetic population, 
card iovascu la r d isease accounts fo r tw o-th irds of the to ta l deaths. 
Cardiovascular disease is more common in NIDDM than IDDM, mostly because 
of the age of the population. As IDDM patients age, the risk increases, but the 
primary cause of death in IDDM is kidney failure. IDDM patients also represent 
a large portion of the kidney transplant patients today. Risk factors for 
card iovascular disease include hypertension, high blood-cholesterol (low
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density lipoprotein, LDL, and very low density lipoprotein, VLDL) with low high 
density lipoprotein (HDL) levels and cigarette smoking. Diabetes is itself a risk 
factor for atherosclerotic cardiovascular disease, increasing the risk two- to 
threefold (ADA, 1991). Hypertension is reported in 50% of the adult diabetic 
population compared to 25% of non-diabetics of the same age.
Lipoproteins are a group of molecules that transport cholesterol throughout the 
blood stream. There are four main types of lipoproteins. Chylomicrons are the 
largest of the lipoproteins and are rich in triglycerides and transport dietary fat 
and cholesterol from the intestine to the liver. Manufactured in the liver, VLDLs 
are also rich in triglyceride and cholesterol, but transport the endogenous forms 
of these lipids. On capillary surfaces, VLDLs and chylomicrons interact with 
lipoprotein lipase causing their triglycerides to be hydrolyzed, producing 
remnants called intermediate density lipoproteins (IDL) which are believed to 
be atherogenic. When VLDLs are metabolized, they form another lipoprotein, 
the LDL. This lipoprotein is high in cholesterol and is referred to as bad 
cholesterol and has a high association with coronary heart disease (Howard 
and Howard, 1994). LDL transport cholesterol from the liver to the peripheral 
tissues. HDL, good cholesterol, acquires free cholesterol from peripheral 
tissues and is este rifled by the enzyme tecithinicholesterol acyltransferase 
(LCAT) to cholesteryl ester which may be transferred to LDL, IDL or VLDL by the 
cholesteryl ester transfer protein (CEPT). Chylomicrons can transform into HDL 
with the transfer of apotipoproteins. One of the consequences of elevated 
lipoproteins is atherosclerosis. In excess, LDLs begin to deposit in artery walls 
accumulate and eventually reduce and possibly totally occlude, blood flow. 
This is atherogenesis. LDL attaches to damaged endothelium and activated 
macrophages and begins to transform macrophages into foam cells with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
cholesterol accumulation. After a period of time, these foam cells become 
calcified and form a plaque. Diabetics, who have excess plasma glucose, also 
run the risk of glycosylating and oxidizing their LDLs. This form of LDL Is more 
likely to be found In atherosclerotic lesions. Oxidized LDL may also recruit 
smooth muscle cells from the media to the Intima and Injure proliferating cells, 
leading to accumulation of dead cells (Autio et al., 1990). Hypertriglyceridemia 
has also been shown to Induce lipid peroxidation and ultim ately aid in 
destruction of cells in areas of atherosclerotic lesions (HIramatsu et al., 1988).
Secondary hyperlipidemia, not attributable to genetics, is often a result of 
metabolic disorders such as diabetes or hypothyroidism, although there are 
many other causes of this condition such as alcoholism. Hyperlipidemia is a 
condition where VLDL and LDL levels are elevated (greater than 160 mg/dl) 
and HDL levels are reduced below 35 mg/dl. Generally, untreated NIDDM 
patients have normal to slightly reduced lipoprotein lipase (LPL) levels, which 
some have shown to Increase with Insulin treatment (Tasklnen, 1987). NIDDM 
patients typically have fasting hypertriglyceridemia and low HDL. The difficulty 
in treating these patients is that they are usually obese and insulin resistant. It 
has even been noted that with tight control of NIDDM, elevated lipids sometimes 
do not decrease. Thus, any treatm ent s tra tegy which can contro l 
hyperglycemia, reduce the elevated triglycerides and LDL cholesterol, and 
increase HDL cholesterol and LPL levels would be a benefit to the NIDDM 
patient.
Myocardial infarction and congestive heart failure occur at a much higher rate In 
diabetic populations (Jaffe, 1989). Reduced diastolic filling rate along with 
prolonged Isovolumic relaxation has been observed In diabetes (Pozzoll et al..
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1984). There are many theories explaining cardiovascular abnormalities in the 
diabetic population, including; deterioration of the microcirculation (Friedmann, 
1989), abnormalities in the conduction system (Garber and Neely, 1983), 
abnormalities in the myocardium such as depressed myocardial metabolism 
(Fevury et al., 1979), impaired tissue antioxidant status (Wohaieb and Godin, 
1987), and decreased sarcolemmal enzyme activity (Pierce et al., 1983). The 
exact mechanism causing or initiating diabetic cardiomyopathy is unknown; 
however, intracellular calcium is believed to be crucial (Pierce, 1988; Weir, 
1990, Ganguly et al, 1983). It is known that the calcium pump of the 
sarcoplasmic reticulum, which controls calcium removal in normal tissue, is 
defective in diabetic tissue, as evidenced by decreased ATP-dependent 
calcium transport and calcium stimulated ATPase activity (Ganguly et al., 1983). 
Calcium regulation is impaired by other mechanisms as well, including: 
decreased Na+-K+ (Pierce et al, 1990), Na+-H+ (Pierce et al, 1990), and Na+- 
Ca++ exchange processes (Makino et al., 1987), and inhibition of Ca ATPase 
(Heyliger et al., 1987).
Cardiac performance abnormalities have been shown in many drug induced 
and genetic animal models of type I diabetes. There is very little evidence 
suggesting cardiovascular problems with type II models of diabetes. A standard 
method of determining cardiac performance is the working heart model. This 
procedure allows one to test the ability of the heart to respond to changes in 
preload. Transducers measure maximum and minimum pressures in the heart 
and heart rate. With a computer program, left ventricular developed pressure 
(LVDP), rate of contraction (+dP/dT), and rate of relaxation (-dP/dT) can be 
measured directly in a heart that is perfused through the pulmonary vein and 
out the aorta.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Much recent evidence suggests that tight control of blood glucose and the 
elimination of as many risk factors as possible can delay, if not prevent, the 
development of these diabetic complications. Appropriate lifestyle changes are 
often sufficient to eliminate the signs and symptoms of NIDDM. In fact, NIDDM 
patients are first treated with education and lifestyle changes including weight 
loss and exercise. Only as a last resort are patients with NIDDM treated with 
drug therapy.
1.3 Insulin
Among the important historical discoveries with insulin are the clin ical 
description of the disease in 20 A.D., the discovery of pancreatic islets by 
Langerhans in 1869, the discovery of insulin in 1921 by Banting and Best, the 
isolation and crystalization of insulin by Abel in 1927 and the synthesis of 
recombinant human insulin in E. coli in 1979.
Insulin is a peptide hormone manufactured and released from the pancreas. 
Insulin mRNA is transcribed in the nucleus of the p islet cell. A fter being 
modified, the mRNA leaves the nucleus and begins the translation process on 
the rough endoplasmic reticulum. Here, a single chain of pre-pro-insulin is 
made. This is also where the pre (24 amino acids) segment is cleaved. The pro 
insulin is released in m icrovesicles which are taken up into Golgi where 
packaging into granules occurs. In the granules three disulfide bonds form 
between cys residues and the C-peptide segment (86 amino acids) is cleaved 
from the pro insulin leaving equal amounts of C-peptide and insulin which are 
secreted into the portal blood. Insulin exists as an A chain (20 amino acids) and
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a B chain (30 amino acids) linked by two disulfide bonds with an intra-A 
disulfide bond. It is released in response to as little as a 10 mg/dl increase in 
plasma glucose levels as well as by amino acids, free fatty acids, glucagon, and 
other less potent secretagogues and sympathetic nervous stim ulation (3 
adrenergic, epinephrine).
Insulin is released from the 3 cells into the blood where it binds to membrane 
bound receptors at target tissues and facilitates glucose uptake into the tissues 
where it can be used. If glucose cannot be used, the body relies on free fatty 
acids and amino acids as precursors. This can lead to muscle wasting, weight 
loss and ketoacidosis. Insulin's actions are anabolic and anti-ketogenic and 
favor the storage of fat, protein and carbohydrate. Insulin decreases 
glycogenolysis, lipolysis, proteolysis and gluconeogenesis. Counter-regulatory 
hormones to insulin include glucagon, epinephrine, growth hormone and 
cortisol. Fifty percent of endogenous insulin is removed by the liver with most of 
the remaining insulin excreted by the kidneys.
The insulin receptor consists of 4 protein subunits, 2 a  and 2 3- It is proposed 
that 2 insulins bind to the 2 a-subunits of the insulin receptor resulting in 
autophosphorylation of tyrosine sites on the 2 3-subunits. The tyrosine kinase 
activity catalyzes the phosphorylation of serine kinases or phosphoprotein 
phosphatases, which phosphorylate or dephosphorylate target enzymes 
resulting in the alteration of metabolic pathways typical of insulin action. In 
contrast, the glucose transporter is not phosphorylated in response to insulin 
and the transporter is translocated to the plasma membrane to take up glucose. 
C e llu la rly , insulin  secretion is stim ulated when in trace llu la r ca lcium  
concentrations increase due to depolarization of a resting cell. Insulin clears
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glucose from the blood by preventing the liver from releasing additional glucose 
and by enhancing glucose transport into muscle and fat cells.
There are 5 known glucose transporters. They are termed GLUT 1-5. These 
different transporters are located in different tissues and differ in terms of the 
glucose requirements of each tissue. Some transporters are found in the same 
tissue. GLUT 1 and GLUT 3 transporters are found in most tissues; whereas 
GLUT 4 is found primarily in muscle and fat; GLUT 2 is found in liver; and GLUT 
5 is found in the small intestine and kidney. There is a 20 fold increase in 
glucose transporters when muscle and fat are exposed to insulin. This involves 
recruitment of transporters from the cytoplasm to the surface and increases in 
the maximum transport capacity of those already there. To enter the cell, 
glucose first occupies its binding site on the outside of the cell. Next, the 
glucose molecule with its transporter change conformation so that the glucose 
now occupies the binding site that faces into the cell. The transporter then 
releases the glucose into the cytoplasm and then changes its conformation to 
face outward again (Lienhard et al., 1992).
1.4 Insulin Resistance
Insulin resistance occurs when the pancreas makes insulin, but for some 
reason the insulin is not very effective at promoting the transport of glucose from 
the blood into the cells of the body. There are many who believe that insulin 
resistance is due to a specific insulin-receptor gene defect. Some believe that 
this insulin-receptor mutation contributes to insulin resistance in a sub­
population of NIDDM patients (O’Rahilly et al., 1991; Cocozza et al., 1992; Kim 
et al., 1992). Insulin resistance has also been implicated in a number of other
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disorders such as obesity, essential hypertension, lipid abnorm alities and 
a therosclerotic card iovascular disease (Reaven, 1988; DeFronzo and 
Ferranninni, 1991). Although genetic defects have been implicated in some 
cases of insulin resistance, it is believed that most insulin resistance occurs at 
the postreceptor level (Clauser et al., 1992).
There are three types of insulin resistance: prereceptor (involving insulin
structure, degradation or function), receptor defects (defects of insulin receptors 
at the surface of cells) and post receptor insulin resistance (Kahn, 1985). 
Mechanisms for prereceptor insulin resistance include mutation of the insulin 
gene, increased degradation of insulin and formation of anti-insulin antibodies 
which block insulin's action. Defects in insulin receptors include decreased 
numbers of receptors, decreased affinity of the receptor for insulin or defective 
tyrosine kinase.
There are currently several animal models used to study insulin resistance. The 
first animal used to study this phenomenon was the mouse. These mice are 
obese and diabetic. There are three strains of mice including C57BL/GJ obese 
(ob), KK mice and their hybrids, C57BL/Ks (db) and the NZO (New Zealand 
obese) mouse. Rats with concurrent diabetes and obesity include the Zucker 
fatty (fa). Diabetic fatty (ZDF/Drt-fa), Wistar-Kyoto diabetic and Wistar-Kyoto fatty. 
A newer strain of rat used to study diabetes is the corpulent SHR/N-cp with 
nephropathy, the SHHF/Mcc-cp with congestive heart failure, and the Jcr;LA-cp 
with ischaem ic card iovascular disease. Corpulent strains tend to be 
hypertensive diabetic rat strains. There are other more obscure models to study 
insulin resistance and/or other NIDDM-like syndromes. However, the models 
mentioned offer symptoms believed to most closely simulate human NIDDM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
12
Animal models of NIDDM are reviewed in two recent papers (Shafrir, 1992 and 
Bailey and Flatt, 1993).
1.5 Drug Therapy for NIDDM
Most NIDDM patients can be treated successfully without drugs. Initial therapy 
is always diet, exercise and education. This is particularly true for the patient 
who is obese since insulin resistance can be caused by obesity. Weight loss 
and exercise are both associated with a decrease in insulin resistance. The 
primary aim in treating diabetes is to relieve symptoms, improve, quality of life 
and prevent both acute and chronic com plica tions (R ifk in , 1988). 
Hyperglycemia has been associated with chronic diabetic complications in both 
animal and human studies. However, this is not always the case. Some 
patients with poor control never develop complications (Pirart, 1978). Since 
insulin resistance and impaired insulin secretion are key factors in the 
pathogenesis of NIDDM, treatment should be directed at restoring intermediary 
metabolism towards normal by improving insulin secretion and reducing insulin 
resistance (Gerich, 1989).
1.5.1 Sulfonylureas
There are five commercially available sulfonylureas in the United States. They 
all consist of a sim ilar sulfonylurea core with different aromatic and alkyl 
substituents that produce pharmacokinetic and pharmacologic differences. The 
sulfonamide group is essential for hypoglycemic action (Loubatieres, 1944). 
This class of drugs is further subdivided. The first generation drugs, discovered 
in the 1960’s, consist of tolbutamide, tolazamide and chlorpropamide. The
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second generation drugs, discovered in the 1970's, consists of glipizide and 
glyburide. Three quarters of the hypoglycemic market from 1964 to 1986 was 
accounted for by three drugs: chlorpropamide, glyburide and glip izide
(Kennedy et al., 1988). Tolbutamide causes the fewest serious side effects of 
all the sulfonylureas; however, it is the shortest-acting and least potent. 
Chlorpropamide is the longest acting and causes the most serious side effects, 
among which hypoglycemia and severe hyponatremia are the most significant. 
Glipizide and glyburide, the most potent of the available agents, are 100 to 150 
times more potent than tolbutamide.
CH3 SOg— NH —C - NH^
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Sulfonylureas stimulate the release of insulin by increasing beta-cell sensitivity 
to glucose so that more insulin is released at every glucose level, but they do 
not increase the synthesis of insulin (Grodsky et al., 1977). It appears that all of 
the sulfonylureas have a similar mechanism of action. A sulfonylurea receptor 
has been found on the p cell and may be closely linked to or part of an ATP- 
sensitive potassium-ion channel. Inhibition of the efflux of potassium ions by 
sulfonylureas may lead to depolarization of the p-cell membrane and the entry 
of calcium which activates protein kinase C associated with exocrine secretory 
granules (Oberwetter et al., 1987; Zawalich et al., 1988) resulting in exocytosis 
of insulin-containing secretory granules. These drugs are ineffective in patients 
without functional p-cells (IDDM); however, some patients will experience 
decreases in g lucose concen tra tions  desp ite  unchang ing insu lin  
concentrations, indicating an increase in insulin receptor binding or insulin 
tissue sensitivity.
Along with decreased plasma glucose, sulfonylureas are known to decrease 
total plasma cholesterol, total triglyceride, and VLDL triglyceride and cholesterol 
with e ither no change (Taskinen et al., 1986) or a modest increase 
(Moorehouse, 1967) in HDL levels.
One of the problems with the use of sulfonylureas is the possib ility of 
hypoglycemic episodes; another is that their use has not been associated with a 
decrease in cardiovascular complications of NIDDM. An additional problem is 
that approximately one th ird of NIDDM patients do not at first achieve 
satisfactory glycémie control with these drugs. The main reason for the failure is 
lack of dietary compliance (Melander, 1988) and severely impaired islet p-cell 
function (Rendell, 1983). Five to ten percent of those patients achieving
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glycémie control have secondary failure after 10 years of treatment with these 
drugs. Other common side effects include gastrointestinal, hematologic, and 
dermatologie reactions in less than 2 percent of patients.
1.5.2 Biguanides
Buformin, phenformin and metformin comprise this chemical class of drugs and 
are not marketed in the United States. Metformin is widely used in Europe and 
Canada, where it accounts for 25 percent of the prescriptions for oral 
hypoglycemic agents (Bailey and Nattrass, 1988). These compounds are 
different from first generation sulfonylureas in that they do not undergo 
biotransformation, are eliminated solely by the kidney and are not bound to 
plasma proteins.
NH NH NHo
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Biguanides contain two linked guanidine molecules. These compounds lower 
blood glucose concentrations by producing insulin-like effects on skeletal
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muscle, liver, kidney and fat (Hermann, 1979), the exact mechanism of action 
being unknown. It is known that they suppress hepatic gluconeogenesis, 
stimulate glycolysis, and inhibit glucose absorption from the intestine (Jackson 
et al., 1987). These agents do not stimulate insulin secretion and are only 
effective in patients with some endogenous insulin. Biguanides are reported to 
not cause hypoglycemia. Interestingly, a recent report states that metformin 
Improves cardiac function in isolated STZ-diabetic rat hearts (Verma and 
McNeill, 1994). Some reports suggest that these compounds cause lactic 
acidosis, but in the 20 years of Metformin use In Canada, there have been no 
cases of lactic acidosis reported (Vigneri and Goldfine, 1987). Phenformin, on 
the other hand, was discontinued in 1977 in the United States due to several 
deaths attributed to lactic acidosis.
1.5.3 Insulin Sensitizers
It was previously indicated that one of the worst side effects of sulfonylurea use 
is severe hypoglycemia resulting from over-stimulation of insulin secretion. This 
suggests that the developm ent of oral hypoglycem ics which control 
hyperglycemia w ithout stimulating insulin release would be an attractive 
alternative. A second pharmacotherapeutic option to treat NIDDM would be to 
restore tissue sensitivity to insulin. Two chemically distinct groups of agents 
have been synthesized which may accomplish this task, vanadyl sulfate (and its 
derivatives) and the thiazotidinediones. Insulin sensitizers are compounds that 
mimic the actions of insulin or increase tissue sensitivity to insulin. One such 
compound, vanadyl, has been shown to possess insulin-like properties in 
various cellular models such as isolated adipocytes, myocytes and hepatocytes 
(Tolman et al., 1979; Dubyak et al, 1980; Clark et al, 1985; Duckworth et al.
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1988; Jackson et al., 1988; Gomez-Foix et al., 1988). This compound is able to 
stimulate glucose transport, inhibit glycogenolysis and inhibit lipolysis. Its 
mechanism of action is still unclear, but it has been suggested that it might work 
by Inhibiting phosphotyrosyl-protein phosphatases (Swarup et al., 1982), 
inducting tyrosine phosphorylation (Tamura et al., 1984; Gherzi et al., 1988; 
Tracey et al., 1986), activating glucose transport through activation of the 
GLUT4 transporter gene (Strout et al., 1990), translocating the transporter from 
the cellu lar organelles to the plasma membrane (Paquet et al., 1990), or 
increaseing intracellular calcium secondary to Ca-Mg-ATPase inhibition (Delfert 
and McDonald, 1985).
O — S — OHo=v
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
18
H iyC 8
C«H8^17
Hz °
NAGLIVAN
Vanadyl's anti-diabetic activities were first demonstrated by Heyliger et al. in 
streptozotocin (STZ)-treated rats, a model of IDDM with some properties in 
common with NIDOM (1985). In these studies, 0.8 mg/m l sodium  
orthovanadate, adm inistered in drinking water, was able to  contro l 
hyperglycemia and prevent the impairment of cardiac function w ithout any 
change in plasma insulin levels in diabetic rats, but decreased levels in control- 
treated rats. This suggests that insulin secretion is not related to the activity of 
vanadium, but that it replaces or potentiates endogenous insulin. It was 
interesting to discover that vanadate prevented insulin-resistance in STZ- 
induced diabetic rats (Blondel et al., 1989) and ob/ob genetically obese mice 
(Brichard et al., 1990) and corrected blood glucose in BB spontaneously 
diabetic (type I) rats (Ramanadham et al., 1990).
Vanadyl sulfate and other related compounds, bis(molatolato)oxovanadium 
(BMOV) and naglivan, work by a similar mechanism of action to reduce insulin 
resistance and restore euglycemia. BMOV reduces insulin resistance and 
normalizes plasma glucose levels in STZ-diabetic rats and improves the 
diabetic pathology observed in non-treated diabetic rats relative to non-diabetic 
rats (Dai et al., 1993). Similarly, vanadyl's  actions mimic insulin by increasing 
glucose transport in adipose and m uscle tissues, increasing glucose
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metabolism, activating glycogen synthesis and inhibiting the breakdown of 
triglycerides. In addition, it has been shown that vanadyl can reduce non­
diabetic plasma insulin levels without affecting plasma glucose. This implies 
that vanadyl works by potentiating insulin's action (Ramanadham et al., 1989).
Vanadium has some reported toxicity, particularly d igestive intolerance 
(diarrhea) leading to dehydration and death of animals. Vanadyl sulfate has 
fewer toxicity problems. This compound exhibits the same glucose lowering 
effects and after chronic treatment, the effects can still be seen 13 weeks after 
cessation of treatment (Ramanadham et al., 1989). It is doubtful that this is due 
to accumulation in tissues since the blood and kidney levels (main depot sites) 
were barely detectable (Ramanadham et al., 1989).
Given vanadyl's effectiveness at lowering plasma glucose and reversing insulin 
resistance, it has been proposed as a potential therapy in human diabetes in 
general, and in insulin-resistant states in particular (Cros et al., 1992). Vanadyl 
has the ability to prevent the myocardial and metabolic abnormalities seen in 
diabetic rats during treatment as well as 13 weeks after withdrawal from vanadyl 
(Ramanadhan et al., 1989). It has been suggested that this effect is due to 
normalization of plasma insulin levels and that insulin has a positive inotropic 
effect in the heart (Ramanadhan et al., 1989).
1.5.4 Thiazolidinediones
The most recent chemical class of oral hypoglycemics to be introduced is the 
th iazo lid ined iones (5 -(4 -a lkoxybenzy l)-2 ,4 -th iazo lid ined iones). These 
compounds appear to reduce insulin resistance or potentiate insulin action in
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genetically diabetic and/or obese animals (Sohda et al., 1992), but do not 
induce hypoglycemia. The presence of a pyridyl ring on the p-alkoxy chain of 
the benzyl moiety is necessary for biological activity. Another Important factor 
for activity is the location of the pyridine nitrogen a  to the oxyethyl chain (Sohda 
et al., 1992). It has also been reported that the 4-oxybenzyl group and the 2,4- 
thiazolidinedione moiety are necessary for hypoglycemic and hypolipidemic 
activities (Momose et al., 1991), respectfully.
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Given the known effects of this class of drugs, it appears that the primary effect 
of these drugs is to improve peripheral target tissue responses to insulin. It has 
been suggested that these effects are due to enhanced post-binding events 
mediating insulin action (Hofmann and Coica, 1992). One example is the 
demonstration of increased GLUT 4 glucose transporter expression. This was 
observed in epididymal fat pads of insulin resistant KKAV mice after treatment 
with pioglitazone (Hofmann et al., 1991). This effect was seen only in animals 
where insulin was present (NIDDM) (Hofmann et al., 1991), supporting the 
hypothesis of an amplified insulin signal.
The first of these compounds to be synthesized in large quantities was 
c ig lita zo n e , 5-[4-(1-m ethylcyclohexylm ethoxy)benzyl]thiazolidine-2,4-dione, 
(AD-3878, U-63,287). It was discovered by scientists at Takeda Chemical 
Industries, Ltd., of Osaka, Japan, (Sohda et al., 1982; Fujita et al., 1983). This 
co m p o u n d  n o rm a liz e s  h y p e rg ly c e m ia , h y p e r in s u lin e m ia  and 
hypertriglyceridemia in various animal models of insulin resistance (Fugita et 
al., 1983; Chang et al., 1983) including KKAY mice (Ikeda et al., 1990; Fujiwara 
et al., 1988), Wistar Fatty rats (Ikeda et al., 1981) and ob/ob mice (Fujiwara et 
al., 1988; Stevenson et al., 1990). This compound requires a dose of 100 
mg/kg/day to lower glucose in ob/ob and db/db mice (Chang et al., 1983).
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Trog litazone , (CS-045), [(±)>5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl- 
m e thoxy)benzy l]-2 ,4 -th iazo lid ined ione ] is ano ther com pound in the 
thiazoiidinedione group. In animal experiments using insulin resistant Zucker 
Fatty rats, it was determined that 150 mg/day p.o. of this compound improved 
glucose tolerance and decreased insulin levels after oral glucose loading due 
to increasing insulin responsiveness (Fujiwara et al., 1988). It was also 
demonstrated that troglitazone increased insulin binding, increased insulin 
receptor numbers in adipocytes and enhanced both insulin sensitivity and 
responsiveness (Fujiwara et al., 1988). Along with these effects, troglitazone 
decreased plasma lactate, free fatty acids and ketone body levels without 
decreasing food intake or body weight (Fujiwara et al., 1988). This is an 
important finding since it has been suggested that body weight loss improves 
glucose tolerance and that this is what causes the glycémie improvements. In 
all studies conducted with this compound, mean body weight did not change 
suggesting that improved glucose tolerance is not due to body weight loss in 
patients.
In the first clinical study with troglitazone, 204 patients were given either 200 or 
400 mg per day either alone or in combination with sulfonylureas. Kuzuya and 
coworkers were able to find a dose-dependent glucose lowering effect with 
25% efficacy with 200 mg/day and 46% efficacy with 400 mg/day (Kuzuya et al., 
1991). They also found that the drug was as effective with or w ithout the 
addition of sulfonylureas. This suggests that troglitazone works by a different 
mechanism than that of the sulfonylureas. These researchers found some 
adverse effects associated with the drug including gastrointestinal problems 
(6%), decreased red blood cell count (3.5%) and increased LDH levels (6%)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
23
(Kuzuya et al., 1991). In other clinical studies using the same 400 mg/day dose, 
it was determined that hemoglobin A ic  was also decreased (Iwamoto et al., 
1991) and that the use of this drug was associated with significantly increased 
HDL-cholesterol levels (Suter et al., 1992). Suter was able to determine that 
the increased HDL is comparable to that achieved with lipid-lowering drugs in 
hyperlipidémie patients (Frick et al., 1987). The inverse relationship between 
plasma HDL-cholesterol concentrations and card iovascular risk is well 
established; this compound would be useful in those NIDDM patients at high 
risk of developing cardiovascular complications.
E n g li ta z o n e  (CP-68722), [(± .)-5 -[(3 ,4 -d ih y d ro -2 -p h e n y fm e th y l-2 H -1  - 
benzopyran-6-yl)methyl}thiazolidine-2,4-dione, is another compound in this 
class. This compound, given at a dose of 5-50 mg/kg/day to ob/ob mice, 
showed a dose-dependent glucose and insulin lowering effect and decreased 
free fatty acids, glycerol, triglycerides and cholesterol after 11 days of treatment, 
but not after a single dose (Stevenson et al., 1990). It also reversed the defects 
in Insulin-stimulated glycolysis and glycogenesis and basal glucose oxidation 
in isolated soleus muscle with no hypoglycemic effects seen in either the 
treated control or diabetic groups (Stevenson et al,, 1990). This compound 
appears to be able to normalize plasma glucose at lower doses than either 
ciglitazone or troglitazone.
In studies using 3T3-L1 adipocytes, englitazone overcame insulin resistance 
primarily by increasing Vmax of 2-deoxyglucose uptake. Like insulin, it appears 
to stimulate glucose uptake by a mechanism that involves translocation of 
intracellular glucose transporters to the plasma membrane and de novo protein 
synthesis since the uptake of glucose could be inhibited by protein synthesis
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inhibitors and was temperature dependent (Kreutter et al., 1990). These effects 
are greater and require lower doses than those seen with sulfonylureas. 
Interestingly, sulfonylureas require insulin to exert their full effect. Sulfonylureas 
alone can induce the expression of glucose transporters, but require insulin for 
translocation to the cell membrane (Wang et al., 1989). Englitazone can do 
both independent of insulin. This suggests it might be an insulinomimetic rather 
than a true sensitizer. The other thiazolidinediones have not been tested for 
this.
P io g lita zo n e , (5-[4-[2-(5-etyl-2-pyridyl)ethoxy]benzyl]-2,4-th iazolid lnedione 
(AD-4833), the final member of this class of drugs, has been studied extensively 
for its glucose and lipid lowering effects in animals. There have been no 
studies concerned with the potential beneficial or deleterious cardiovascular 
effects of the drug. These are concerns regarding clin ical use since 
pioglitazone has been reported to cause cardiac enlargement at doses 
considered therapeutic (CoIca, J., personal communications). As with other 
compounds of the th iazoiid inedione drug class, p ioglitazone corrected 
abnormalities in glucose, lipids and insulin in KKAY mice (2.4-24.5 mg/kg/d for 4 
days) and Zucker fatty rats (0.1-10 mg/kg/d for 4 days) (Ikeda et al., 1990). As 
seen with the other thiazolidinediones, pioglitazone lowered plasma glucose 
and lipids in obese animals, but not in lean or STZ-diabetic rats, suggesting that 
the lipid and glucose lowering effects are associated with reduced insulin 
resistance and enhanced insulin action on peripheral tissues (Ikeda et al., 
1990). When ED25 values were compared in KKAY mice, pioglitazone was 
much more potent (6 mg/kg/d) than was ciglitazone (31 mg/kg/d) (Ikeda et al., 
1990). The ability of pioglitazone to decrease plasma glucose, insulin, 
triglycerides and fatty acids is dose dependent as is its promotion of body
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weight gain (the higher the dose, the greater the absolute weight gain) (Ikeda et 
al., 1990).
Pioglitazone, when given at a dose of 3 mg/kg/day for 6 days, has been shown 
to decrease insulin resistance in peripheral tissues and livers of Wistar fatty rats, 
while having no effect on the lean litter mates (Sugiyama et al., 1990a). This 
was determined by the observation that pioglitazone restored hepatic glycogen 
production and peripheral glucose utilization in the presence of infused insulin 
in fatty rats. In addition, glucose-6-phosphatase decreased and glucokinase 
increased, suggesting an increased response of the liver to insulin and a 
resulting suppression of hepatic glucose production (glycolytic pathway 
becomes dominant against gluconeogenic pathway). These findings suggest 
that pioglitazone also reduces insulin resistance via hepatic enzyme regulation 
(Sugiyama et al., 1990a). These studies also indicate that pioglitazone can 
normalize plasma glucose levels at a much lower dose than the other 
thiazolidinediones.
In addition to the effects on liver insulin resistance, it was determined that 
pioglitazone increased insulin-stimulated glycogen synthesis and glycolysis in 
the isolated soleus muscle and insulin stimulated glucose oxidation and 
lipogenesis in adipocytes without any effect on insulin binding (Sugiyama et al.,
1990b). Vanadate, the insulinomimetic, which is known to work at post receptor 
binding sites, was potentiated by pioglitazone, suggesting that the glucose and 
lipid lowering effects of the drug are caused by reducing insulin resistance at 
post-receptor binding sites (Sugiyama et al., 1990b).
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Pioglitazone has been shown to inhibit cholesterol absorption and to lower 
plasma cholesterol concentrations in cholesterol-fed rats (Coica et al., 1991). 
These effects only occur when insulin is present, working synergistically to 
lower absorption of cholesterol and circulating cholesterol and triglycerides 
(Coica et al., 1991). It has been suggested, given the aforementioned results, 
that treatments that improve insulin sensitivity may also have a positive impact 
on coronary artery disease associated with diabetes. Although the plasma 
cholesterol levels in rats not fed a high cholesterol diet did not change, the 
lipoprotein profiles were different. In KKAY mice, the majority of plasma 
cholesterol is carried in HDL and HDL levels are very high (Castle et al., 1993). 
Pioglitazone is known to lower elevated lipids in other animal models such as 
insulin resistant obese Rhesus Monkeys and although the exact mechanism is 
unknown, it does enhance triglyceride clearance rate (Kemnitz et al., 1994) 
possibly through stimulation of lipoprotein lipase or triglyceride lipase.
As mentioned earlier, GLUT4 glucose transporters are membrane proteins 
expressed only in tissues in which glucose uptake is regulated by insulin (fat, 
skeletal muscle and heart). In fat and muscle insulin stimulates glucose entry 
by recruiting glucose transporters from intracellu lar pools to the plasma 
membrane (Cushman and Wardzala, 1980). GLUT4 expression is decreased 
in KKAY mice. Pioglitazone corrects the GLUT4 transporter defect (Hofmann et 
al., 1991). This seems to be more prominent in fat than muscle and requires the 
presence of insulin. GLUT2 transporters, the major liver glucose transporters, 
re m a in e d  u n ch a n g e d  by p io g lita z o n e  tre a tm e n t; h o w e v e r ,  
phosphoenolpyruvate carboxykinase (a m ajor rate-lim iting enzym e for 
gluconeogenesis) activity, which is elevated in untreated diabetics, was
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normalized, suggesting that pioglitazone restored sensitivity to insulin's normal 
inhibitory actions (Hofmann et al., 1992).
To further determine the mechanisms by which pioglitazone decreases insulin 
resistance, insulin receptor kinase levels were evaluated. Pioglitazone caused 
no change in receptor binding in W istar fatty rats, but increased insulin- 
stimulated autophosphorylation of insulin receptors to 78% over the level in the 
control (Kobayashi et al., 1992). Kinase activity affecting the exogenous 
substrate poly Glu^Tyr^ also increased to 87% over control obese rats. Lean 
rats trea ted  w ith  p iog litazone , how ever, show ed no change  in 
autophosphorylation and kinase activity (Kobayashi et at., 1992). These results 
suggest that pioglitazone increased insulin sensitivity in part by activating the 
kinase of its receptors through indirect effects on insulin receptors. It was 
suggested that if the conformational change occurs when insulin binds to its 
receptor, pioglitazone may potentiate the change to activate kinase or signal 
transduction between the two subunits of the receptor (Kobayashi et al., 1992). 
This effect was seen in the skeletal muscle of rats fed a high fat diet (Iwanishi 
and Kobayashi, 1993). These cumulative results suggest that pioglitazone's 
ability to decrease insulin resistance may result from improving the sensitivity of 
target tissues to insulin rather than from a direct corrective action of the agent on 
glucose transporters (Hofmann et al, 1991). It could be acting through a 
pathway other than activating tyrosine kinase in the insu lin -s ignaling 
mechanism and the increased kinase activity may reflect only a secondary 
effect of metabolic improvement (Iwanishi and Kobayashi, 1993).
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1.6 General Hypothesis
A new chemical class of antidiabetic agents, the th iazolid inediones, by 
correcting or preventing insulin resistance in genetica lly d iabetic animal 
models, can cause physiologic or metabolic changes that may reduce the risk of 
developing one or more cardiovascular complications of type II diabetes.
1.7 Objectives
1. To determine the ability of pioglitazone, a thiazoiidinedione, to prevent or 
correct (reverse) diabetic hyperglycemia in 3 sets of genetically diabetic 
(NIDDM) rats known to exhibit a phase of hyperinsulinemia (insulin resistance). 
To fulfill this objective, plasma glucose (every two weeks), insulin (every two 
weeks) and glycosylated hemoglobin (at termination) were determined.
a. Administered prior to onset of hyperglycemia (vs. no drug) —
In young ZD F rats (7 weeks of age at initiation of treatment)
b. Administered after onset of hyperglycemia (vs. no drug, 
hydralazine and vanadyl) -  In older ZDF rats (13 weeks of age at 
initiation of treatment)
c. Administered prior to onset of hyperglycemia diabetic rats which
may be prone to develop hypertension or congestive heart failure 
(vs. no drug, hydralazine and vanadyl) — In young ZDF/SHHF rats 
(6 weeks of age at initiation of treatment)
2. (a,b,c) To determine if the prevention or correction of hyperglycemia by
pioglitazone is paralleled by corrections in plasma triglycerides, cholesterol, 
lipoproteins or free fatty acids, elevations of which may be associated with
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enhanced rates of atherogenesis and whether pioglitazone causes favorable or 
unfavorable effects on HDL cholesterol.
3. (a.b.c) To determine whether cardiovascular abnormalities exist in the 
animal models of insulin resistance listed in objective 1, and whether correction 
of insulin resistance with pioglitazone is associated with beneficial changes in 
the following cardiovascular parameters:
heart size and heart weight vs. body weight ratios
i. cardiac lipid profiles: cholesterol and triglycerides
ii. aortic (vascular) sensitivity
V. cardiac performance
4. (b,c) To evaluate the usefulness of ZDF or ZDF-SHHF rats as models of 
hypertension associated with NIDDM and to assess the potential of pioglitazone 
or other thiazolidinediones to treat hypertension by altering the state of insulin 
resistance.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2 .0  M E T H O D S
2.1 Study Groups
Study la , 2a, and 3a were conducted using twenty-four young male Zucker 
Diabetic Fatty Rats (ZDF, Drt-/a), obtained from Genetic Models, Indianapolis, 
Indiana, and twenty-three male, non-diabetic, Zucker Lean Rats (ZL) littermates. 
These groups were each divided into two sub-groups: one received 10 
mg/kg/day pioglitazone MCI suspended in sodium citrate, administered by oral 
gavage, while the other group received the vehicle (0.5 M sodium citrate). The 
subdivision of animals resulted in four groups which will be designated control 
(GU, n=11), control treated (CP, n=12), diabetic (DU, n=12), and diabetic treated 
(DP, n=12). Diabetes was not chemically induced, rather, these genetically 
derived  n on -insu lin -dependen t-d iabe tic  rats becam e spon taneous ly  
hyperglycemic between 7 and 10 weeks of age. Treatment was initiated in all 
groups of rats at 7 weeks of age and continued for 6 weeks to a final age of 13 
weeks at study termination. Diabetic rats were housed individually in hanging 
metal cages and lean rats were housed in shoebox cages. They were housed 
in a 12 hour light-dark cycle environment and received food (Purina 5008 rat 
chow) and water ad libitum. All animals were allowed a minimum of 5 days to 
acclimate before initiation of experiments.
Studies 1b, 2b, 3b and 4b used the same animal model (ZDF rats), however, 
the rats used were of an older age. Treatment was begun when they were 13 
weeks of age (rather than 7) having fully established hyperglycemia and 
continued 8 weeks rather than 6, ending at 21 weeks of age. This study also 
involved additional treatment groups. Along with pioglitazone treated animals
30
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(10 mg/kg/day) and vehicle treated control animals, one group of animals 
received vanadyl (incremental dosages from 0.05 mg/ml to 0.75 mg/ml 
adm inistered in deionized drinking water ad libitum) and another group 
received hydralazine (5 mg/kg twice daily by oral gavage). The subdivision of 
animals resulted in 8 groups, which were designated control (CU, n=5), control 
treated (CP, n=5), diabetic (DU, n=5), diabetic treated (DP, n=5), control 
hydralazine (CH, n=4), diabetic hydralazine (DM, n=4), control vanadyl (CV, 
n=5) and diabetic vanadyl (DV, n=5). Initially DH and CH began with 5 rats, but 
one rat in each group died. Ttiese rats were housed identically to the first group 
of rats, but were fed Purina 5015 rat chow which Is higher in fat.
Studies 1c, 2c, 3c and 4c consisted of a young hybrid animal model. These rats 
are a hybrid between the ZDF model and the SHHF (spontaneously 
hypertensive) animal models. Treatment was begun at 6 weeks of age and 
continued for 8 weeks to age 14 weeks at termination. The subdivision of 
animals resulted in 8 groups which will be designated control (CU, n=7), control 
treated (CP, n=7), diabetic (DU, n=7), diabetic treated (DP, n=7), control 
hydralazine (CH, n=4), diabetic hydralazine (DH, n=4), control vanadyl (CV, 
n=4) and diabetic vanadyl (DV, n=4). Lean rats were housed in metal hanging 
cages and diabetic rats in shoebox cages, as in the other studies, and received 
the same regular rat chow as in studies la , 2a, and 3a.
2.2 Drug Therapy
Pioglitazone hydrochloride was provided by Jerry Coica, Ph.D., Upjohn Co., 
(Kalamazoo, Ml) and was suspended in 0.5 M sodium citrate (Sigma, St. Louis,
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MO), pH 4.5, by homogenization with a Biohomogenizer (M 133/1281-0, Fisher 
Scientific, Fair Lawn, New Jersey), before administration to rats by oral gavage 
at a dose of 10 mg/kg/day. In study la , 2a, and 3a, dosages were calculated 
and administered each day at 2:00 pm. In the other studies, drugs were 
administered at approximately 8:00 am daily. An equivalent volume (1 ml/kg) of 
sodium citrate vehicle was administered as a vehicle control to the non-treated 
animals via the same method for studies a and b.
Hydralazine, 5 mg/kg, (Sigma Chemical Co., St. Louis, MO) was dissolved in 
deionized water and administered twice daily (approximately 12 hours apart) by 
oral gavage.
Vanadyl Sulfate (Eastman Kodak Co., Rochester, NY) was dissolved in 
deionized drinking water to reduce oxidation. The concentration was changed 
every 3 (+) days from an initial concentration of 0.05 mg/ml to a final 
concentration of 0.75 mg/ml which is known to correct IDDM. This approach 
was used to minimize toxicity due to dehydration. If an animal failed to drink 
adequate amounts of fluid, the dosage was reduced for a day until the animal 
rehydrated.
As an overt measure of drug toxicity, animals were observed on a daily basis to 
ensure that no diarrhea was present and their body weights were recorded. 
The animals were given water ad libitum and were fed regular rat chow, Purina 
Chow 5008, Richmond, Indiana in a and c studies, but were fed Purina 5015 in 
the b studies.
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All other chemicals for general lab use (buffers, etc.) were obtained from Fisher 
Scientific Co., Fair Lawn, NJ.
2.3 Measurement of Plasma Components
Blood was removed from pentobarbital anesthetized rats at study termination 
through the abdominal aorta using a 22 gauge needle attached to a 10 cc 
plastic syringe, containing a small amount of the anticoagulant EDTA. Blood 
was centrifuged at 4°C for 10 minutes in a Beckman Model TJ-6 Centrifuge at 
2000 rpm and the plasma was separated and distributed into several microfuge 
tubes for plasma analyses. Plasma analyses included glucose, cholesterol, 
triglycerides, free fatty acids and insulin. All plasma samples were stored at 
-70°C for later analyses. Some termination plasma samples were analyzed on 
an automated chemical analyzer (Hitachi) while most were analyzed using 
common biochemical kits (see section 2.3.1).
Blood was also collected at week 0, 2, 4, 6 and 8 for time course evaluation of 
plasma triglycerides, cholesterol and insulin. These samples were obtained 
through the tail vein by nicking the tail with a sterile scalpel and stroking the tail 
to collect the blood in microfuge tubes containing EDTA. Blood was separated 
and plasma stored at -20 ®C for later analyses.
2.3.1 Glucose, Triglyceride and Cholesterol Determinations
Blood glucose was measured weekly on a One Touch II Glucose Analyzer 
(Johnson and Johnson Co., Milpitas, California) using One Touch test strips.
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For these samples, the blood was obtained from the tail. These values were 
determined weekly using this method on 5 hour fasted rats.
On weeks 2, 4, 6 and 8 , plasma glucose and triglycerides were determined 
using Stanbio enzymatic colorimetric kits obtained from Fisher Scientific Co., 
Fair Lawn, NJ. Cholesterol was determined using a similar procedure with kits 
obtained from Sigma Chemical Co., St. Louis, MO. The standard procedure for 
all of these kits was to use 10 |xt of plasma plus 1 ml of reagent and incubate for 
10 minutes followed by reading the optical density on a Bausch and Lomb 
Spectrophotometer at 500 nm.
2.3.2 Free Fatty Acid Determinations
Free fatty acids from a and b studies were measured at study termination using 
a chloroform extraction technique followed by colorimetric determination of free 
fatty acid levels following the methods of Buncombe,WW (1963), as modified by 
Itaya, K, and Ui, M (1965). For study c, a m icro-assay technique from 
Boehringer Mannheim, Indianapolis, Indiana, was used. Determinations were 
made at weeks 0, 4 and 8.
2.3.3 Plasma Insulin Determinations
Plasma insulin was determined at weeks 0, 2, 4, 6 and 8 weeks. Plasma insulin 
was measured using a double antibody radioimmunoassay obtained from Unco 
(Linco Research Inc., St. Louis, MO) according to the method of Morgan and 
Lazarow (1963). This kit uses polyclonal antibodies raised in guinea pigs 
against rat insulin (100% specific to rat insulin). The assay used labeled rat
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insulin of specific activity 0.02 pCi per sample. The sensitivity of the assay as 
used was 0.1 ng/ml. Intra and inter assay coefficients of variation were 1.34% 
and 3.17%, respectively.
2,4 Measurements of Cardiac Function
Following six or eight weeks of oral drug treatment, the rats were overdosed 
with Pentobarbital Sodium (Fort Dodge Laboratories, Inc., Iowa) 100 mg/kg i.p. 
A fter loss of pain and righting reflexes, rats were exanguinated via the 
abdominal aorta with a 10 ml plastic syringe and a 22 g needle. The blood was 
centrifuged and separated for later plasma analyses. During the exanguination 
process, the heart was rapidly removed and placed into a dish of warm 
Chenoweth-Koelle (OK) buffer for transport to the working heart apparatus. The 
heart was first cannulated through the aorta, according to the Langendorff 
procedure, and perfused with warm, oxygenated (95% O2 and 5% CO2), OK 
buffer (millimolar concentrations of: NaCi, 120; KOI, 5.6; CaCl2 , 2.18; MgCl2 ,
2.1 ; NaHCO s, 19.2; and glucose, 10). Once the pulmonary vein was 
cannulated, the system was switched to an isolated working heart preparation. 
This allows perfusion first through the left atria into the left ventricle and finally 
out the aorta. The buffer was not recirculated. PE-10 tubing was used to 
provide resistance. The experiment involved subjecting the heart to changes in 
preload and observing changes in cardiac performance. The criteria measured 
were left ventricular developed pressure (LVDP), rate of force development 
(+dP/dT) and rate of relaxation (-dP/dT) as previously described (Rodrigues and 
McNeill, 1986). At the completion of the working heart analysis, the whole heart 
was weighed to determine the heart weight to body weight ratio then freeze
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clamped In liquid nitrogen to preserve samples for subsequent determinations 
of myocardial triglyceride and cholesterol levels.
2.5 Blood Pressure
Blood pressure values were determined for each rat in study b and c. This 
method involves the use of a semi-automated, amplified tail cuff inflation device 
from IITC Inc., Woodland Hills, Califomia, Rats were placed in appropriately 
sized holders and sensors and allowed to acclimate to the surroundings for 20- 
30 minutes. The tail inflation device containing a light sensor was subsequently 
inflated to 300 mmHg and allowed to deflate in a linear fashion. The amplifier 
transfers the signal from the sensor and translates it into a blood pressure trace 
which is seen on the chart recorder. From this tracing, systolic blood pressure 
can be measured from the initial pulses on the trace and the mean arterial 
pressure is measured from the first maximum pulse. The diastolic pressure is 
calculated from the systolic and mean pressures. The calculation is as follows:
D.P.= 3(mean)-systoiic 
2
2.6 Vascular Reactivity
Endothelium dependent relaxation is believed to be impaired in IDDM, but is 
questionably affected in NIDDM; thus a series of experiments was designed to 
investigate this phenomenon in NIDDM by measuring aortic sensitivity. Aortic 
sensitivity was measured by determining the ability of 4 mm aortic rings to 
contract in the presence of norepinephrine. Aortic strips were taken from the
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region just distal to the aortic arch of the heart. A 4 mm strip was suspended in 
a water jacketed tissue bath containing 25 ml of Krebs buffer (containing mM 
concentrations of: NaCI, 118; KCI, 4.7; CaCl2, 2.5; NaHC0 3 , 25; KH2PO4 , 12; 
MgS0 4 , 1.2; Glucose, 11) and oxygenated with 95% O2 and 5% CO2 at 37®C' 
Two grams of resting tension was placed on the strip to provide resistance 
against which to contract. The tissue was held in place by two small fish hooks 
which are attached to an F-60 Myograph Pressure Transducer (Narco 
Biosystems). The contractions were translated by the coupling device and 
produced a read out on the physiograph (Narco Biosystems).
The tissue was first allowed a 30 minute equilibration period. Then, to establish 
whether the tissue worked, the aortic strip was suspended in a high potassium 
bath (40 mM KCI; replacing NaCI). The tissue's ability to contract due to 
depolarization of the membrane indicated that the strip was working. A 
norepinephrine (NE) dose response curve was determined on each strip of 
tissue using concentrations of NE from 10~9 M to 10"® M. Norepinephrine is an 
alpha-adrenergic agonist in blood vessels which causes contraction of the 
vascular tissue. Contractile force was expressed in grams.
2.7 Statistics
Comparison between group means was accomplished using a one way 
analysis of variance (ANOVA) followed by Scheffe's F-test, where applicable. A 
probability of p<0.05 was used to indicate statistical significance.
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3 .0  R E S U L T S
For the purpose of convenience, the legends in the figures have been 
condensed to two letter acronyms for most treatment groups as follows:
CU Control/ untreated rats DU Diabetic untreated rats
CP Control pioglitazone DP Diabetic pioglitazone
CV Control vanadyl DV Diabetic vanadyl
CH Control hydralazine DH Diabetic hydralazine
NOTE: Control refers to non-diabetic rats.
To review, the study groups are as follows:
a. Administered prior to onset of hyperglycemia (vs. no drug) —
In young ZDF rats (7 weeks of age at initiation of treatment)
b. Administered after onset of hyperglycemia (vs. no drug,
hydralazine and vanadyl) — In older ZDF rats (13 weeks of age at 
initiation of treatment)
c. Administered prior to onset of hyperglycemia diabetic rats which
may be prone to develop hypertension or congestive heart failure 
(vs. no drug, hydralazine and vanadyl) — In young ZDF/SHHF rats 
(6 weeks of age at initiation of treatment)
3.1 Body Weights
Body weights of young (7-13 weeks of age) ZDF diabetic rats were significantly 
greater than their non-diabetic littermates throughout the study. After one week 
of oral treatm ent with 10 mg/kg/day pioglitazone HCI, body weights were
38
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significantly higher than the untreated diabetic rats. Six weeks of pioglitazone 
treatm ent caused a -1 .5  fold greater increase in body weight relative to 
untreated diabetics and -1 .8  fold increase over control rats. Non-diabetic rats 
had a steady body weight increase whether given pioglitazone or not (FIG. 1).
Body weights of older ZDF diabetic rats were significantly higher than non­
diabetic littermates at 13 weeks of age. After 7 weeks of treatment (20 weeks of 
age), body weight was not significantly different except in the vanadyl treated 
group (FIG. 28). Vanadyl lowered body weights in both diabetic and non­
diabetic older ZDF rats. Pioglitazone and hydralazine had no effect on body 
weight gain in the older ZDF rats (FIG. 2A.C).
At 6 weeks of age (before treatment) young hybrid ZDF/SHHF diabetic rats (DU, 
DP) did not have elevated body weights compared to their non-diabetic 
littermates (CU). Unexpectedly, randomization of the control rats led to the CV 
and CH groups beginning treatment at a lower body weight than either the CU 
or DU groups. After 3 weeks of pioglitazone treatment (9 weeks of age) body 
weights of the DP group were significantly elevated compared to DU and by the 
end of the 8 weeks of treatment, DP was -1 .25 fold greater than DU (FIG. 3A). 
There was no effect on body weight observed in the non-diabetic group 
following pioglitazone treatment. Also at 9 weeks of age, the body weights of 
the DU group became significantly elevated compared to the CU group and 
remained elevated throughout the rest of the study. CU body weights exceeded 
those of the CV and CH rats throughout the study. Vanadyl significantly 
decreased body weight in the diabetic group after 8 weeks of treatment. 
Hydralazine had no effect on body weight in either diabetic or non-diabetic rats 
(FIG. 3B,C).
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FIG. 1 Time course of oral pioglitazone effect on body weight in young ZDF 
diabetic rats and non-diabetic littermates. Data represent the means 
±  SEM. Error bars smaller than symbols are not shown.
#, significantly different from diabetic untreated from this point through week 13. 
*, significantly different from control untreated from this point through week 13.
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FIG. 2. Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine 
effects on body weight in older ZDF diabetic rats and non-diabetic littermates. 
Data represent the means ±  SEM. Error bars smaller than symbols are not 
shown. #, significantly different from diabetic untreated. *, significantly 
different from control untreated.
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FIG. 3. Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine 
effects on body weight In young hybrid ZDF/SHHF diabetic rats and non­
diabetic littermates. Data represent the means ±  SEM. Error bars smaller than 
symbols are not shown. #, significantly different from diabetic untreated from 
this point through 14 weeks of age. *, significantly different from control 
untreated from this point through 14 weeks.
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3.2 Plasma Glucose
Fasting plasma glucose levels of 7 week old young ZDF rats were not 
significantly different from levels in control rats. By 9 weeks of age, DU plasma 
glucose levels were significantly elevated relative to those of CU and CP rats. 
Fasted plasma glucose levels were significantly reduced by pioglltazone in 
young ZDF diabetic rats beginning near the time of developing hyperglycemia. 
After two weeks of treatment with pioglltazone, glucose levels of diabetic rats 
were com plete ly norm alized and rem ained so throughout the study. 
Pioglltazone had no effect on the blood glucose in non-diabetic sham treated 
rats (given 1 ml/kg/day of 0.5 M sodium citrate by oral gavage) (FIG.4).
At 13 weeks of age, older ZDF diabetic rats had significantly elevated plasma 
glucoses compared to control rats. Older ZDF diabetic rats, that exhibited 
consistent hyperglycemia, showed no effect from pioglltazone treatment on 
plasma glucose at any point during the 7 weeks of treatment (FIG. 5A). 
However, vanadyl significantly decrease plasma glucose after two weeks of 
treatment with the drug (FIG. 58). During this period of time, rats were subjected 
to steadily increasing concentrations of vanadyl from 0.05 mg/ml to 0.75 mg/ml 
to avoid toxicity. Hydralazine had no effect on plasma glucose (FIG. 5C). 
Pioglltazone, vanadyl or hydralazine had no effect on plasma glucose in non­
diabetic rats (FIG. 5).
At the beginning of treatment in the young hybrid rats (6 weeks old), there was 
no significant difference in blood glucose levels between any of the rat groups. 
Diabetic rats did not develop significantly elevated plasma glucose levels until 
12 weeks of age. As the rats developed hyperglycemia, it was evident that both
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FIG. 4. Time course of oral pioglltazone effect on fasted plasma glucose levels 
in young ZDF diabetic rats and non-diabetic littermates. Data represent the means 
± SEM. Error bars smaller than symbols are not shown. #, significantly different 
from diabetic untreated from this point through 13 weeks. *, significantly different 
from control untreated from this point through 13 weeks.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
45
DU CU DP CP
A  450 
400 
350 
300 
250 
200 
150 
100 
50
13 14 15 16 17 18 19 20
LU
(/>
O
O
3
il
<
DU D VCUB 450 
400 
350 
300 
250 
200 
150 
100 
50
13 14 15 16 17 18 19 20
DHDU CHC 450 
400 
350 
300 
250 
200 
150 
100 
50 
0
14 15 16 17 18 19 2013
F IG .
AGE (weeks)
5 Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
effects on fasting plasma glucose levels in older ZDF diabetic rats and non­
diabetic littermates. Data represent the means ±  SEM. Error bars smaller than 
symbols are not shown. #, significantly different from diabetic untreated from 
this point through week 20. *, significantly different from control untreated from 
this point through week 20.
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FIG 6. Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine 
effects on fasted plasma glucose levels in young hybrid ZDF/SHHF diabetic 
rats and non-diabetic littermates. Data represent the means ±  SEM. Error 
bars smaller than symbols are not shown. #, significantly different from 
diabetic untreated. *, significantly different from control untreated.
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the pioglltazone and vanadyl treatment groups had significantly lower plasma 
than the untreated diabetic rat group (FIG. 6A,B). Hydralazine treatment was 
without effect in the diabetic or non-diabetic groups (FIG. 6C). Pioglltazone, 
vanadyl or hydralazine had no effect on the non-diabetic rats.
3.3 Plasma Triglycerides
At seven weeks of age, young ZDF diabetic rats already had significantly higher 
plasma triglyceride levels ( -  7 times) than the non-diabetic littermates. Within 2 
weeks, pioglltazone normalized the elevated triglyceride levels and maintained 
these levels throughout the study (FIG. 7).
Thirteen week old, older ZDF diabetic rats had significantly elevated plasma 
triglyceride levels (~5 times) compared to non-diabetic rats. Pioglltazone 
significantly decreased triglyceride levels from DU levels at weeks 3 and 7 of 
treatment (FIG. 8A). Vanadyl had no effect on plasma triglyceride levels in 
diabetic rats (FIG. 8B). Hydralazine treatment significantly decreased plasma 
triglycerides in the diabetic rats at weeks 1, 3 and 7 of treatment (FIG. 8C). 
Control rats, treated with either pioglltazone, vanadyl or hydralazine, had 
significantly lower triglyceride levels compared to CU after 3 weeks of treatment.
Six week old, young hybrid diabetic rats were not hypertriglyceridemic. By 8 
weeks of age, diabetic rats had significantly elevated triglyceride levels which 
progressively increased through 12 weeks of age at which time they plateaued. 
P ioglltazone significantly reduced, but did not normalize, these elevated 
triglyceride levels and had no effect in the non-diabetic rats (FIG. 9A). Vanadyl
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FIG. 7. Time course of oral pioglltazone effect on fasted plasma triglyceride 
levels in young ZDFdiabetic rats and non-diabetic littermates. Data represent 
means ±  SEM. Error bars smaller than symbols are not shown. #, significantly 
different from diabetic untreated from this point through 13 weeks.
*, significantly different from control untreated from this point through 13 weeks.
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FIG. 8 , Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine 
effects on fasted plasma triglyceride levels in older ZDF diabetic rats and 
non-diabetic littermates. Data represent means ±  SEM. Error bars smaller 
than symbols are not shown. #, significantly different from diabetic untreated. 
*, significantly different from control untreated.
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FIG. 9. Time course of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine 
effects on fasted plasma triglyceride levels in young hybrid ZDF/SHHF diabetic 
rats and non-diabetic littermates. Data represent means ±  SEM. Error bars 
smaller than symbols are not shown. #, significantly different than diabetic 
untreated from this point through week 14. *, significantly different from control 
untreated from this point through week 14.
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caused a significant reduction in triglyceride levels compared to DU at week 14 
when vanadyl dosing was at its highest (FIG. 9B). Hydralazine had no effect on 
triglycerides in diabetic or non-diabetic hybrid rats (FIG. 9C).
3.4 Plasma Cholesterol
Fasted plasma values following 6 weeks of vehicle treatment in young ZDF 
diabetic rats (7-13 weeks of age) indicated that DU rats had significantly higher 
glucose, triglyceride, total and HDL cholesterol and free fatty acids than did 
non-diabetic rats. Pioglitazone, administered for 6 weeks, significantly reduced 
the hyperglycemia, hypertriglyceridemia and hypercholesterolemia but had no 
effect on HDL or free fatty acid levels in the DU rats . Pioglitazone given to non­
diabetic rats had no effect on any of the mentioned plasma parameters (Table 
1).
Older ZDF diabetic rats (13-20 weeks of age) exhibited significantly elevated 
fasted glucose, triglycerides, total cholesterol, free fatty acids and hemoglobin 
A1c than did control rats after 7 weeks of treatment. There was no difference 
between CU and DU with respect to HDL cholesterol. Insulin values were 
s ign ifican tly  reduced in d iabetic groups compared to contro l groups. 
Pioglitazone and hydralazine treatment groups had plasma triglyceride levels 
that were intermediate between those of DU and CU rats. Vanadyl significantly 
reduced plasma glucose in diabetic rats. Only pioglitazone significantly 
decreased free fatty acid levels relative to CU and DU rats (Table 2).
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TABLE 1. Effect of oral pioglitazone treatment on plasma glucose, triglycerides, total and HDL 
cholesterol, free fatty acids and insulin after 6 weeks of treatment in young ZDF diabetic rats and non­
diabetic littermates.
PLASMA
PARAMETER
DU
(n=12)
DP
(n=12)
CU
(n=11)
CP 1
(n=12)
Glucose
(mg/dl)
285.6 ± 30.0 * 109.8 ±8.1 # 92.4 ± 4.0 # 96.8 ± 6.2 #
Triglycerides
(mg/dl)
613.8 ±54.1 * 148.7 ±16 .2 # 95.9 ± 14.6 # 67.0 ± 5.0 #
Total Cholesterol 
(mg/dl)
174.0+14.0* 135.0 ± 1 1 .0 * # 82.0±11.0# 78.0 ± 9.0 #
HDL Cholesterol 
(mg/dl)
147.0 ±29 .0 * 121.0 ±21 .0 * 64.0 ± 7.0 # 64.0 ± 1 2 .0 #
FFA
(pmol/l)
127.0 ±10 .6 * 123.4 ±15 .2* 39.0 ± 8 .2 # 49.2 ± 5.8 #
Insulin
(ng/ml)
16.6 ±2.6 29.5 ± 3.0 * 12.4 ±2.4 9.6 ±2.4
HbAtc
(percent)
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NOTE; A dash indicates that this parameter was not measured. Results represent means ± SEM; n, 
number of animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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TABLE 2. Effect of oral pioglltazone, vanadyl and hydralazine treatment on plasma glucose, triglycerides, total
and HDL cholesterol, free fatty acids and insulin after 7 weeks of treatment in older ZDF diabetic rats and non­
diabetic littermates.
PLASMA
PARAMETER DU
(n=5)
DP
(n=5)
DV
(n=5)
DH
(n=4)
CU
(n=5)
CP
(n=5)
CV
(n=5)
CH
(n=4)
Glucose
(mg/dl) 350.2 * 
±5.9
330.8 * 
±12.5
229.4 #* 
± 17.0
299.5 * 
±9.3
108.6 # 
±7.1
94.2#
±6.2
92.6 # 
± 1.1
90.0#
±6.6
Triglycerides
(m^dl) 694.2 * 
± 117.3
481.6 r  
±49.5
565.0 * 
±71.5
471.8 #* 
±34.8
158.2 # 
±21.9
106.8 # 
±7.2
95.8#
±22.2
68.3# 
± 17.5
Total
Cholesterol
(mg/dl)
153.6
±13.4*
147.4 ± 8.4* 132.4 ±6.9* 142.8 ± 8.2* 56.6 ±2.65# 53.4 ±1 .2 # 68.2 ± 4.0 # 51.5 ±3 .3 #
HDL
Cholesterol
(mg/dl)
83.6 ± 37.4 55.1 ± 19.5 71.1 ±14.9 95.5 ± 14.7 39.2 ± 2.2 36.3 ±1.4 49.0 ± 3.5 38.5 ±1.6
FFA
(timol/l) 292.8 * 
±25.1
247.9 * 
±15.4
245.3 * 
±40.9
300.4 * 
±28.9
171.5 # 
±3.6
142.8 #* 
±9.7
173.68 # 
±6.4
195.4 # 
±40.8
Insulin
(ng/ml) 5.9 ±1.9 * 3.2 ±0.4 * 6.8 ±1.0 * 5.0 ±0.6 * 22.6 ± 7.4 # 14.1 ±2 .8# 6.3 ±1 .4 # 17.7 ± 4 .5 #
HbAtc
(percent) 8.7 ±0.4 * 9.5 ±0.4 * 0.2 ±0.4 * 9.6 ±0.6 * 5.7 ±0 .4 # 5.8 ±0 .4 # 6.1 ±0 .7 # 6.6 ±1 .3 #
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NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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TABLE 3. Effect of oral pioglitazone, vanadyl and tiydralazine treatment on plasma glucose, triglycerides, total 
and HDL cholesterol, free fatty acids and insulin after 8 \weeks of treatment in young hybrid ZDF/SHHF diabetic 
rats and non-diabetic littermates.
fPLASMA
PARAMETER DU
(n=7)
DP
(n=7)
DV
_Ln=4)
DH
(n=4)
CU
(n=7)
CP
( n ^
c v
(n=4)
CH
(n=4)
1 Glucose 
(mg/dl) 304.8
±34.9*
195.1
±10.5#
239.4
±15.5#*
365.3
±45.0*
170.3 
± 8.0 #
158.6
±7.0#
156.2
±17.6#
170.4
±5.4#
Triglycerides
(mg/dl) 1267.2 
± 142.2*
328.9 
± 35.0#*
755.9 
± 243.2#*
1197.6 
± 235.8*
128.1 
± 10.8#
77.1
±4.5#
70.2 
± 13.3#
62.2
±8.3#
Total
Cholesterol
(mq/dl)
189.1 
± 11.4*
92.2
±6.5#
149.2 
± 24.4*
102.8 
± 17.0#*
79.6 
± 10.0#
54.7
±3.7#
59.0
±6.3#
54.7
±6.1#
HDL
Cholesterol
(mg/dl)
67.6 + 1.6* 61.6 ±3.3* 72.0 ± 4.2* 78.5 ±1.4*# 48.1 ± 2.0# 39.7 ±1.6# 44.7 ± 6.7# 41.2 ±2.1#
FFA
(umol/l) 259 ± 20 253 ± 26 262 ± 31 276 ± 10 247± 11 186 ±19 230 ± 62 243 ± 22
Insulin
(ng/ml) 33.8 ± 5.2* 13.1 ± 1.6# 26.6 ± 3.5* 29.4 ± 8.7* 7.2 ±1.1# 5.3 ± 0.4# 5.7 ± 2.1# 7.1 ±1.5#
HbAlc
(percent) 6.39
±0.4*
5.20 ± 
0.38#
6.33 
± 0.47*
6.67 
± 0.59*
4.22 
± 0.34#
4.66 
± 0.40#
5.06 
± 0.39#
4.68 
± 0.82#
NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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Young hybrid ZDF/SHHF diabetic rats (6-14 weeks of age) showed significantly 
elevated fasted plasma glucose, triglycerides, total and HDL cholestérols, 
insulin and hemoglobin A le  compared to CU rats following 8 weeks of 
treatment (Table 3). Pioglitazone normalized plasma glucose, total cholesterol, 
insulin and hemoglobin A le  in the DP group and significantly decreased 
triglycerides relative to DU. Vanadyl significantly reduced plasma glucose and 
triglyceride levels whereas hydralazine significantly reduced total and elevated 
HDL cholesterol levels. There was no effect by any drug on control rats. There 
was no difference between any groups with respect to free fatty acid levels.
3.5 Cardiac Performance
Cardiac performance was measured by three parameters: left ventricular
developed pressure (LVDP), rate of force development by the left ventricle 
(+dP/dt), and rate of relaxation by the left ventricle (-dP/dt). LVDP was not 
affected by diabetes alone (DU) at any of the preload pressures from 7.5 to 22.5 
cm H2O in young ZDF diabetic rats (FIG. 10), in older ZDF diabetic rats (FIG. 11) 
or In young hybrid ZDF/SHHF diabetic rats (FIG. 12). Pioglitazone treatment 
caused a significantly reduced function in young ZDF diabetic rats at the two 
lowest preloads (7.5 and 10 cm H2O) compared to CU rats. In young hybrid 
ZDF/SHHF rats, pioglitazone caused control rats to have significantly improved 
function at the three highest preloads (17.5, 20 and 22.5 cm H2O) compared to 
CU (FIG. 12A). Vanadyl and hydralazine did not influence LVDP in either 
diabetic or non-diabetic rats in either older ZDF (FIG. 11 B,C) or young hybrid 
ZDF/SHHF rats (FIG. 12B,C).
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Rate of force development (+dP/dt) was also not affected by diabetes in young, 
old or hybrid ZDF diabetic rats compared to non-diabetic rats (FIG. 13, 14, 15). 
As with LVDP, pioglitazone treatment significantly reduced diabetic heart 
function, at the two lowest preloads tested (7.5 and 10 cm H20) in young ZDF 
diabetic rats (DP; FIG. 13), but not in the older ZDF diabetic or young hybrid 
ZDF/SHHF diabetic rats compared to CU (FIG. 13). Young ZDF diabetic rats 
have impaired function compared to CU rats, but this trend was not seen in 
older ZDF diabetic rats or young hybrid ZDF/SHHF diabetic rats. Vanadyl and 
hydralazine had no significant effect on rate of force development in either 
diabetic or control young, old or hybrid ZDF rats (FIG. 14B.C; 15B.C).
Rate of ventricular relaxation (-dP/dt) showed similar responses to +dP/dt and 
LVDP in that there was no significant effect of untreated diabetes on this 
cardiovascular parameter in old, young or hybrid ZDF diabetic rats relative to 
non-diabetic littermates. A trend seems apparent, suggesting that diabetic 
hearts have impaired function in young ZDF diabetic rats (FIG. 16). 
Pioglitazone significantly Impaired diabetic heart function, but only at the two 
lowest preloads tested (7.5 and 10 cm H20) in the young ZDF diabetic rats (FIG. 
16). Hydralazine caused diabetic rat hearts to relaxed significantly slower (- 
dP/dt) than control hearts at the three highest pressures (17.5, 20 and 22.5 cm 
H20) and caused hearts of the CH rats to have significantly increased function 
at the same three high pressures compared CU or DU (FIG. 17C). Pioglitazone 
and vanadyl had no effect on -dP/dt in diabetic or non-diabetic older ZDF and 
young hybrid ZDF/SHHF rats (FIG. 17A,B; 18A,B). Hydralazine also affected 
-dP/dt in young hybrid ZDF/SHHF diabetic hearts (FIG. 18C). Diabetic hearts 
exposed to hydralazine had significantly elevated rates of relaxation compared 
to CU at the 4 highest preloads (15, 17.5, 20 and 22.5 cm H20).
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FI G. 10. Influence of oral pioglitazone on left ventricular developed pressure 
(LVDP) in isolated working hearts of young ZDF diabetic rats and non-diabetic 
littermates. Results illustrate the LVDP as left atrial filling pressures changed at
2.5 cm H 20 intervals from 7.5 to 22.5 cm. Data represent mean ±  SEM.
*, significantly different than control untreated.
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FIG. 11. Influence of oral (A) pioglitazone, (B) vanadyl and (0) hydralazine on 
left ventricular developed pressure (LVDP) in isolated working hearts of older 
ZDF diabetic rats and non-diabetic littermates. Results illustrate the LVDP as left 
atrial filling pressures changed at 2.5 cm H 20 Intervals from 7.5 to 22.5 cm.
Data represent means + SEM. *, significantly different from control untreated.
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FIG. 12. Influence of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine 
on left ventricular developed pressure (LVDP) in isolated working hearts of 
young hybrid ZDF/SHHF diabetic rats and non-diabetic littermates. Results 
illustrate LVDP as left atrial filling pressures changed at 2.5 cm H 20 intervals 
from 7.5 to 22.5 cm. Data represent mean + SEM. *, significantly different 
than control untreated.
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FIG. 13 Influence of oral pioglitazone on rate of force development (+dP/dt) 
In isolated working hearts of young ZDF diabetic rats and non-diabetic litter­
mates. Results illustrate +dP/dt in the left ventricle as left atrial filling 
pressures changed at 2.5 cm H 20 intervals from 7.5 to 22.5 cm. Data 
represent mean ±  SEM. *, significantly different from control untreated.
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FIG. 14. Influence of oral (A) pioglitazone, (B) vanadyl and (G) hydralazine 
on rate of force development (+dP/dt) In isolated working hearts of older ZDF 
diabetic rats and non-diabetic littermates. Results illustrate the +dP/dt In the 
left ventricle as left atrial filling pressures changed at 2.5 cm H 20 intervals 
from 7.5 to 22.5 cm. Data represent mean ±  SEM.
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FIG. 15. Influence of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine 
on rate of force development (+dP/dt) in isolated working hearts in young 
hybrid ZDF/SHHF diabetic rats and non-diabetic littermates. Results illustrate 
the +dP/dt in the left ventricle as left atrial filling pressures changed at 2.5 cm 
H 20 intervals from 7.5 to 22.5 cm. Data represent mean ±  SEM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6 3
DU CU DP — ù   CP
6000
5000-
4000-
€  »  
?!
3000-
2000 -
1000 -
t.
LEFT ATRIAL FILLING
(cm H 20)
PRESSURE
FIG. 16. Influence of pioglitazone on rate of relaxation (-dP/dt) In 
Isolated working hearts of young ZDF diabetic rats and non-diabetic 
littermates. Results illustrate the -dP/dt of the left ventricle as left 
atrial filling pressures changed at 2.5 cm H 20 Intervals from 7.5 to 
22.5 cm. Data represent mean ±  SEM. *, significantly different than 
control untreated.
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FIG. 17. Influence of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine 
on rate of relaxation (-dP/dt) in isolated working hearts in older ZDF diabetic 
rats and non-diabetic littermates. Results illustrate the -dP/dt of the left 
ventricle as left atrial pressures changed at 2.5 cm H 20 intervals from
7.5 to 22.5 cm. Data represent mean ±  SEM. #, significantly different 
from diabetic untreated. *, significantly different from control untreated.
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FIG. 18 Influence of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine 
on rate of relaxation (-dP/dt) in isolated working hearts of young hybrid 
ZDF/SHHF diabetic rats and non-diabetic littermates. Results illustrate the 
-dP/dt of the left ventricle as left atrial filling pressures changed at 2.5 cm 
H20 intervals from 7.5 to 22.5 cm. Data represent mean ±  SEM.
*, significantly different from control untreated.
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3.6 Vascular Reactivity
Vascular reactivity was measured by determining the ability of aortic rings to 
contract after incremental doses of norepinephrine (NE). Data were compiled 
as dose response cun/es. In older ZDF diabetic rats, aortic sensitivity to NE was 
s ign ifican tly  increased compared to untreated non-diabetic litterm ates. 
Pioglitazone significantly attenuated the aortic sensitivity of DU rats, but does 
not normalize it to CU levels. Pioglitazone had no effect on responsiveness in 
non-diabetic rats (FIG. 19A). Vanadyl lowered NE responsiveness similarly, but 
more potently and completely than pioglitazone relative to aortas of DU rats. 
Vanadyl was without effect on non-diabetic rats (FIG. 19B). Hydralazine not 
only failed to reduce aortic sensitivity to NE, but actually increased sensitivity 
above that seen in tissues from untreated diabetic rats. Regardless of diabetic 
status or drug treatment, vascular reactivity was not changed in young hybrid 
ZDF/SHHF rats (FIG. 20A,B,C).
The maximal response to NE was significantly elevated in older ZDF diabetic 
rats compared to CU rats. Pioglitazone and vanadyl decreased NE sensitivity in 
diabetic rat aortas. Hydralazine, on the other hand, significantly increased 
sensitivity in non-diabetic rats with no effect relative to DU (Table 4), The 
maximal response to NE in young hybrid ZDF/SHHF diabetic rats was not 
d ifferent than that of non-diabetic rats, nor did piogitazone, vanadyl or 
hydralazine have any sigificant effect on this parameter (Table 5).
The maximal response to 40 mM KOI was also significantly higher in older ZDF 
diabetic rats compared to CU rats. Pioglitazone and vanadyl significantly 
reduced these levels in diabetic rats while vanadyl and hydralazine significantly
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FIG. 19 Effect of oral (A) pioglitazone, (B) vanadyl and (G) hydralazine 
on norepinephrine dose response curves in isolated aorta of older ZDF 
diabetic rats and non-diabetic littermates. Data represent mean ±  SEM. 
#, significantly different from diabetic untreated from that point throug 
the rest of the curve. ", significantly different from control untreated 
from that point through the rest of the curve.
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FIG. 20 Effect of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine 
on norepinephrine dose response curves in Isolated aorta of young 
hybrid ZDF/SHHF diabetic rats and non-diabetic littermates. Data 
represent mean ±  SEM.
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TABLE 4. Effect of oral pioglitazone, vanadyl and fiydralazine on the maximal response to 40 mM KCI and 
norepinephrine (NE) after 7 weeks of treatment in older ZDF diabetic rats and non-diabetic littermates.
DU (n=5) DP (n=5) DV (n=5) DH (n=4) CU (n=5) CP (n=5) CV (n=5) CM (n=4)
40 mM KCI 
(grams of 
tension)
1.60 ±0.12* 1.06 ±0.05*# 1.08 ±0.12*# 1.30 ±0.06* 0.63 ± 0.09 # 0.68 ±0.10# 1.10 ±0.12*# 1.08 ±0 .25#
MAX. NE 
RESPONSE 
(grams of 
tension)
2.68 + 0.05* 1.66 +0.04*# 1.24 ±0.10# 2.60 ± 0.12 * 1.03 ±0.13# 1.06 ±0.07# 1.30 ±0 .09# 1.95 ±0.06*#
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NOTE: Data represent means ±  SEM; n, number of animals. Numbers represent fasted values. 
#Significantly different from diabetic untreated.
‘Significantly different from control untreated.
O
c
g
CO
CO
CDQ.
"O
83"O2Q.
CDQ1
o
N
TABLE 5. Effect of oral pioglitazone, vanadyl and fiydralazine on ttie maximal response to 40 mM KCI and 
norepinepfirine (NE) after 8 weeks of treatment in young fiybrid ZDF/SHHF diabetic rats and non-diabetic 
littermates.
DU (n=7) DP (n=7) DV (n=4) DH (n=4) CU (n=7) CP (n=7) CV (n=4) CH (n=4)
40 mM KOI 
(grams of 
tension)
0.44 ± 0.08 0.40 ± 0.08 0.38 ± 0.05 0.53 ±0.10 0.44 ± 0.09 0.44 ± 0.07 0.40 ± 0.06 0.43 ± 0.06
MAX. NE 
RESPONSE 
(grams of 
tension)
0.78 + 0.25 0.39 ±0.10 0.33 + 0.13 0.50 ±0.11 0.61 ± 0.18 0.46 ± 0.06 0.30 ± 0.10 0.50 ± 0.06
NOTE: Data represent means ± SEM; n, number of animals. Numbers represent fasted values. 
#Significantfy different from diabetic untreated.
•Significantly different from control untreated.
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Increased the response in non-diabetic littermates (Table 4). In young hybrid 
ZDF/SHHF rats there was no significant difference with respect to the response 
to 40 mM KCI in any treatment group (TableS).
3.7 Cardiovascular Parameters
Additional cardiovascular parameters measured included systolic and diastolic 
blood pressure, mean arteria l blood pressure, cardiac cholesterol and 
triglycerides, heart weight and heart weight to body weight ratios. Systolic, 
diastolic and mean arterial blood pressures were not measured in young ZDF 
diabetic and non-diabetic rats due to lack of necessary equipment. Cardiac 
cholesterol did not differ between diabetic and non-diabetic rats and no effect 
was observed with pioglitazone treatment. There was a significant difference 
between diabetic and non-diabetic levels of cardiac triglycerides. Pioglitazone 
treatment lowered cardiac triglycerides in both diabetic and non-diabetic rats. 
P ioglitazone s ign ifican tly  increased heart sizes in diabetic rats and in 
conjunction with significantly elevated body weights resulted in significantly 
lower heart weight to body weight ratios compared to untreated and non­
diabetic rats (Table 6).
Hydralazine, but not pioglitazone or vanadyl, significantly decreased systolic, 
diastolic and mean arterial blood pressures in both diabetic and non-diabetic 
older ZDF rats. Cardiac cholesterol in diabetic rats was significantly decreased 
compared to non-diabetic rats. Hydralazine, but not pioglitazone and vanadyl, 
significantly decreased cardiac cholesterol in control rats with no effect seen in 
diabetic rats. Cardiac triglycerides are significantly higher in diabetic compared
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to non-diabetic rats. Vanadyl therapy significantly reduced elevated cardiac 
triglyceride levels in DU rats. Diabetic heart weight and body weights were not 
sign ificantly  d ifferent from heart weights in non-diabetic rats. Vanadyl 
significantly lowered body weights in both diabetic and non-diabetic rats and 
significantly lowered heart weights in diabetic rats. None of the drug treatments 
modified heart weight to body weight ratios (Table 7).
Although a relative trend appears for hydralazine to decrease systolic, diastolic 
and mean arterial blood pressures in young hybrid ZDF/SHHF rats compared to 
untreated diabetic and non-diabetic young hybrid ZDF/SHHF rats, significant 
changes were not observed. Pioglitazone did decrease systolic, diastolic and 
mean arterial blood pressures in diabetic rats compared to CU rats. Cardiac 
cholesterol and triglyceride levels were not altered by pioglitazone, vanadyl or 
hydralazine in either diabetic or non-diabetic rats. Pioglitazone treatment 
caused significantly increased heart weights in diabetic rats compared to CU 
and DU. Diabetic rats had significantly elevated body weights compared to 
control rats. Pioglitazone treatment significantly increased the body weights of 
diabetic rats whereas vanadyl significantly decreased body weights compared 
to DU rats. Vanadyl and hydralazine treatment also significantly reduced body 
weights in non-diabetic rats compared to CU and DU rats; however, this 
phenomenon occurred from the initiation of the study and was probably not 
reflective of drug effect. Heart weight to body weight ratios were significantly 
increased by hydralazine in control rats but not diabetic rats.
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TABLE 6. Effect of oral pioglitazone treatment on systolic, diastolic and mean arterial pressures, cardiac
cholesterol and triglycerides, heart weight, body weight and heart weight to body weight ratio after 6 weeks of
treatment in young ZDF diatietic rats and non-diabetic littermates.
1 CARDIAC 
1 PARAMETER
DU
(n=12)
DP
(n=12)
CU
(n=11)
CP
(n=12)
Systolic/Diastolic
(mmHg)
*“ ""
Mean Arterial 
Pressure (mmHg)
— — —
Cardiac 
Cholesterol 
(nmol/mg protein)
237.5 ± 26.4 217.6126.1 226.0132.1 183.0122.3
Cardiac 
Triglycerides 
(nmol/mg protein)
280.0 ± 35.5 * 168.0125.9# 142.0 1 30.2# 81.0112.8 #*
Heart Weight 
(grams)
1.91210.078 2.22310.087 #* 1.75510.053 1.931 10.068
Body Weight 
(grams)
439.9 ± 7.4 * 633 .4110.7*# 363.4 1 6.8# 379.816.3#
Heart: Body 
Weight Ratio 
(X10-3)
4.3410.15 3.5110.11 *# 4.8510.20 5.0910.18
NOTE; A dash indicates that this parameter was not measured. Results represent means ± SEM; n, number of 
animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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TABLE 7. Effect of oral pioglitazone, vanadyl and hydralazine treatment on systolic, diastolic and mean arterial
blood pressures, cardiac cholesterol and triglycerides, heart weight, body weight and heart weight to body weight
ratio after 7 weeks of treatment in older ZDF diabetic rats and non-diabetic littermates.
CARDIAC
PARAMETER DU
(n=5)
DP
(n=5)
DV
(n=5)
DH
(n=4)
CU
(n=5)
CP
(n=5)
CV
(n=5)
CM
(n=4)
Systolic/
Diastolic
(mmHg)
143/105 140/116 140/102 104#*/78 * ' 136/111 145/111 142/105 101**/80#'
Mean Arterial 
Blood 
Pressure 
(mmHg)
118±8 124 ± 8 116±11 91 ± 7 * ' 120 ±10 126 ± 6 117±7 8 7 ± 8 # '
Cardiac
Cholesterol
(nmoVmg protein)
13.80 ±1.9* 18.07 ±1.5 15.26 ±2.8 16.08 ± 3.6 20.78 ±1.0# 16.20 ± 1.6 18.68 ± 1.9 7.55 ± 0.6#*
Cardiac
Triglycerides
(nmol/mg protein)
16.08 ±1.6* 18.96 ±2.0* 9.10 ±1.1 # 24.1±3.0#* 8.17 ±0.4# 5.81 ± 0.7# 4.70 ± 0.6# 7.54 ± 0.3#
Heart Weight 
(grams) 1.7 ±0.1 1.8 ±0.2 1.3 ±0.1# 1.6 ±0.1 1.7 ±0.2 1.7 ±0.1 1.4 ±0.1 1.6 ±0.2
Body Weight 
(grams) 450.0 
± 10.8
472.8
±9.8
347.6 
± 14.7#*
432.8
±8.0
442.6 
± 17.1
495.6 
± 13.8
354.0
±9.2#*
432.8
±20.5
Heart:Body 
Weight ratio 
(X 10 -3 )
3.83 ± 0.04 3.88 ± 0.19 3.84 ± 0.08 3.73 ±0.12 3.83 ±0.11 3.51 ± 0.13 4.00 ±0.11 3.74 ± 0.22
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NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted plasma values. 
#Significantly different from diabetic untreated.
‘ Significantly different from control untreated.
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TABLE 8. Effect of oral pioglitazone, vanadyl and fiydralazine treatment on systolic, diastolic and mean arterial
blood pressure, cardiac cholesterol and triglycerides, heart weight, body weight and heart weight to body weight
ratio after 8 weeks of treatment in young hybrid ZDF/SHHF diabetic rats and non-diabetic littermates.
CARDIAC
PARAMETER DU
(n=7)
DP
(n=7)
DV
(n=4)
DH
(n=4)
CU
(n=7)
CP
(n=7)
CV
(n=4)
CH
(n=4)
Systolic/
Diastolic
(mmHg)
130/88 117*/78* 140/94 118/79 154/106 140/93 149 /104 125/77
Mean Arterial 
Blood 
Pressure 
(mmHg)
103 ±6 91+4* 109 ± 8 92±6 123 ± 4 109 ± 7 119±12 93 ±17
Cardiac
Cholesterol
(nmoVmg protein)
10.81 ± 1.3 12.71 ± 1.5 12.30 ± 2.1 13.75 ±2.7 9.72 ±1.2 12.03 ± 2.0 13.24 ± 3.7 16.72 ± 2.0
Cardiac
Triglycerides
(nmol/mg protein)
8.49 ± 1.4 8.68 ±1.6 8.53 ±1.3 9.05 ±1.6 4.67 ± 0.3 5.70 ± 0.7 4.92 ±1.4 9.33 ± 1.75
Heart Weight 
(grams) 1.818 
± 0.034
2.027 
+ 0.049 #*
1.738 
± 0.058
1.737 
± 0.013
1.760 
± 0.027
1.883 
± 0.039
1.534
±0.13
1.741 
± 0.063
Body Weight 
(grams) 571+6* 708 + 8#* 541 ±7# * 548 ± 16* 446 ± 6 # 469±10# 360 ± 14 #* 385 ± 14#*
HeartiBody 
Weight ratio 3.186 
+ 0.067 *
2.866 
± 0.074 *
3.209 
± 0.074 *
3.174 
± 0.068 *
3.952 
± 0.082 #
4.027 
± 0.099 #
4.248 
± 0.240 #
4.542 
± 0.204 #*
NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted values. 
#Significantly different from diabetic untreated.
•Significantly different from control untreated.
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4 .0  D I S C U S S I O N
Increased body weight is apparently an important factor in insulin resistance 
and hyperlipidem ia in NIDDM. This is particularly true In obese NIDDM 
patients, in whom It has been shown that significant weight loss through diet 
and exercise can alleviate insulin resistance and possibly eliminate the need to 
take oral hypoglycemic agents. If adequate control can not be attained with diet 
and exercise, drug therapy is necessary.
Zucker D iabetic Fatty (ZDF) rats are hyperinsuliném ie, hyperglycem ic, 
hypertriglyceridemic and hypercholesterolemic and simulate human NIDDM. At 
an older age, these ZDF rats develop IDDM, become hypoinsulinemic and 
remain hyperglycemic, hypertriglyceridemic and hyper-cholesterolemic. Hybrid 
ZDF/SHHF rats maintain the same characteristics of the young ZDF rats, but 
have the added potential of developing hypertension and/or congestive heart 
failure. In all 3 groups of rats, diabetic fatty rats had elevated body weight 
compared to control rats at some point. In the young and older ZDF, this 
Increased body weight occurred from the initiation of the study (7 weeks and 13 
weeks, respectively); however, the significantly increased body weight of young 
hybrid ZDF/SHHF diabetic rats occurred only after the rats reached 9 weeks of 
age.
Pioglitazone, a thiazolidinedione, caused a significant increase in body weights 
in the young ZDF diabetic rats and young hybrid ZDF-SHHF diabetic rats. 
There was not a significant body weight increase in young, old or hybrid non­
diabetic rats treated with pioglitazone. In the older non-diabetic ZDF rats, 
pioglitazone appeared to cause an increase in body weight, but this trend was
76
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not significant. By the end of the study in older ZDF rats (20 weeks of age) all 
diabetic and non-diabetic groups, except the vanadyl treated animals, had body 
weights that were not significantly different from each other. This body weight 
gain is consistent with results seen in KKAV mice (Hofmann et al., 1991) and 
W istar diabetic fatty rats (Sugiyama et al., 1990), even though their pioglitazone 
treatment lasted for a much shorter period of time. Sugiyama (1990) suggests 
that the increased body weight is attributed to increased food consumption in 
W istar fatty rats (a rat model of NIDDM) treated with pioglitazone. It has also 
been shown that the effects of pioglitazone occur only in hyperinsulinémie rats 
and not normal or hypoinsulinemic states (Ikeda, 1990; Hofmann et al., 1991). 
This agrees w ith our study where body weight gains only existed in 
hyperinsulinémie young ZDF and young hybrid ZDF/SHHF rats, but not in 
hypoinsulinemic older ZDF rats. Food consumption was not directly measured 
In our experiments, but increased consumption could be observed on a daily 
basis by visual examination. Increased food consumption has also been 
reported as a result of insulin injection. It would seem that an increase in body 
weight would not be beneficial to NIDDM diabetic patients, the majority of whom 
are already obese; however, these and other studies conclude that there 
appears to be no detrimental effect on plasma components caused by 
pioglitazone.
Vanadyl sulfate treatment in older ZDF diabetic and non-diabetic littermates 
caused a significant reduction in body weights coincidental with a decrease in 
plasma glucose. This effect was also seen in the young hybrid ZDF/SHHF rats, 
but only after 8 weeks of treatment. Perhaps this is because the rats had not 
been at an adequate concentration for a sufficinet period of time since the rats 
were slowly brought up to a concentration known to decrease plasma glucose
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study and at that point there was a significant decrease in plasma glucose in the 
diabetic rats treated with vanadyl. It has been suggested that the antidiabetic 
effects of vanadyl are mediated entirely through its appetite suppression caused 
weight loss (Malabu, U.H. et al., 1994). There are many reports, using pair fed 
animals, which contradict Malabo's theory. In these experiments, obese fa/fa 
rats were treated with food restrictions sim ilar to the reduced consumption 
observed in vanadyl treated rats. These rats were compared to vanadyl treated 
obese fa/fa rats. It was determined that oral vanadate but not food restrictions 
decreased muscle insulin resistance in these obese rats (Brichard, S.M., 1992).
With optimal control of diabetes In humans and rats, plasma glucose levels 
decrease and approach 100 mg/dl. Clinically, fasting plasma glucose greater 
than 150 mg/dl is considered hyperglycemic. In old, young and hybrid diabetic 
rat groups (DU), plasma glucose levels were significantly elevated, albeit at 
different ages. The difference in ages of the animal models at the onset of 
treatm ents (7 weeks, young ZDF; 13 weeks, older ZDF; 6 weeks, hybrid 
ZDF/SHHF) resulted in two groups that were not hyperglycemic (young, a; 
hybrid, c) and one group that was hyperglycemic (older, b). In the young ZDF 
diabetic rats, hyperglycemia (286 ± 30 mg/dl) was established at 9 weeks of 
age; in young hybrid ZDF/SHHF rats, hyperglycemia (305 ±  35 mg/dl) became 
evident at 12 weeks of age. Regardless of treatment, non-diabetic rats did not 
develop hyperglycemia spontaneously nor did they become hypoglycemic after 
pioglitazone, vanadyl or hydralazine treatment.
Pioglitazone administration significantly reduced plasma glucose levels in the 
young ZDF diabetic and young hybrid ZDF/SHHF diabetic rats, but not in the 
o lde r rat group. This is probably a ttribu tab le  to the fact tha t the
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thiazolidinediones require some level of insulin to be effective; by the end of the 
study the older rats had apparently converted from type II (hyperinsulinémie) to 
type I (hypoinsulinemic) diabetics. This was indicated by the significant 
decrease in insulin levels in diabetic rats with respect to non-diabetic rats. This 
indicated a possible destruction of pancreatic p cells that originally tried to 
overcompensate for the elevated glucose levels in the diabetic rats. One 
suggested mechanism for the glucose lowering effect of pioglitazone is to 
stim ulate expression of GLUT 4 glucose transporter mRNA. These new 
transporters subsequently translocate to membranes where they stimulate the 
rapid removal of glucose from the bloodstream into fat and muscle. This 
phenomenon has been observed in several models of insulin resistance in 
adipose tissue and muscle (Hofmann et al, 1991). By increasing transporter 
num ber and stabilizing message expression, stimulation of storage and 
metabolism of glucose can be expected as well as increased insulin sensitivity 
leading to decreased insulin resistance (Sandouk et at., 1993).
Also of interest was the observation that although rats were given a pioglitazone 
dose 3 fold greater than those reported necessary to control plasma glucose, no 
hypoglycemia was observed even when the rats were dosed and fasted 
concurrently. This is a significant advantage over the sulfonylureas in treating 
NIDDM. These compounds are known to cause hypoglycemia, which can be 
severe, as a side effect of treatment.
Hydralazine treatment had no effect on blood glucose levels in any of the rats. 
Vanadyl sulfate, however, did significantly lower plasma glucose in older ZDF 
diabetic rats, but did not normalize plasma glucose, possibly because the dose 
was not given in adequate amounts for a sufficient period of time. Vanadyl at
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maximum concentrations lowered the plasma glucose levels of young hybrid 
ZDF diabetic rats once hyperglycemia was established. Vanadyl has been 
known to reduce plasma glucose levels in ob/ob mice, a model of NIDDM 
(Brichard et al., 1990) and in STZ-diabetic rats, a model of IDDM with low levels 
of circulating insulin (Heyliger et al., 1985).
Vanadyl is known to improve Insulin sensitivity and reduce insulin resistance in 
diabetic rats, consistent with our results from old and hybrid diabetic rats. 
Vanadyl's reported ability to increase the diminished GLUT4 transporters in 
diabetic rats (Strout et al., 1990; Paquet et al., 1990) may be responsible for 
these effects.
Since elevated plasma insulin levels (hyperinsulinemia) are a good indicator of 
NIDDM and insulin resistance and given that the overall mechanism of action of 
p ioglitazone is to reduce insulin resistance, plasma insulin levels were 
determined. If not corrected, hyperinsulinemia in diabetic and/or obese states 
can cause hepatic glucose production to increase and glucose utilization to 
decrease despite the presence of insulin (Defronzo et al., 1982). These 
metabolic abnormalities worsen the diabetes and make control very difficult.
Young ZDF rats maintained moderately elevated insulin values regardless of 
diabetic status. These levels were somewhat greater than those seen in the 
non-diabetic rats of hybrid origin (the other NIDDM group). Older ZDF diabetic 
rats had significantly lowered plasma insulin levels (similar to IDDM) compared 
to non-diabetic rats; whereas, young hybrid ZDF/SHHF diabetic rats had 
significantly elevated insulin levels compared to non-diabetic littermates (similar 
to NIDDM). Pioglitazone did not appear to reduce the hyperinsulinemia seen in
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young ZDF diabetic rats. It also did not have an effect on the already low 
plasma insulin levels of the older ZDF diabetic rats. Pioglitazone did, however, 
significantly reduce plasma insulin levels in young hybrid ZDF/SHHF diabetic 
rats. These results are consistent with NIDDM models where pioglitazone 
works only when insulin is present. This explains why the drug was ineffective 
in the older rats that converted to IDDM with low insulin levels. By the end of the 
treatment period, the control rats had also begun to make the conversion to type 
II diabetes as evidenced by their significantly higher plasma insulin levels 
compared to the diabetic rats. A possible explanation for the failure of 
pioglitazone to eliminate hyperinsulinemia in the young ZDF diabetic rats (DU, 
17 ± 3 ng/ml) might be that their insulin levels never reached the extremely 
elevated levels seen in the young hybrid ZDF/SHHF diabetic rats (DU, 35 ± 5 
ng/ml).
Unlike pioglitazone, which improves insulin sensitivity, vanadyl tends to mimic 
insulin's actions. Vanadyl sulfate mimics the actions of insulin and thus is 
effective in improving glucose tolerance in NIDDM and IDDM models. No 
change in insulin levels were noted with vanadyl or hydralazine in diabetic or 
non-diabetic rats of young, old or hybrid origin.
It has been suggested that the insulin resistance in Wistar Fatty NIDDM rats may 
be ameliorated by the activation of tyrosine kinase activity in insulin receptors 
(Kobayashi et al., 1992). However, in that study, it was never established 
whether this was a secondary effect of metabolic improvement or a direct effect. 
Tyrosine kinase is necessary for property functioning insulin receptors. After 
insu lin  b inds to the a  subunit, the receptor's p subun it undergoes 
autophosphorylation at its tyrosine residues. This results in activation of
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tyrosine kinase which phosphorylates substrates eventually resulting In 
insulin's effects.
Insulin resistance has also been associated with elevated triglycerides and fatty 
acids since fatty acids are preferentially mobilized from adipose tissues and 
glucose disposal is inhibited (Kobayashi et al., 1992). Elevated triglycerides 
and cholesterol and decreased HDL cholesterol levels have been linked to 
Increased incidence of coronary artery disease. Thus it is very important for 
diabetics and others with elevated lipids to normalize their lipids. This is 
especia lly true for d iabetics who have a higher incidence of vascular 
abnormalities such as hypertension as a consequence of their disease.
Pioglitazone significantly lowers the elevated triglycerides observed in young, 
older and hybrid diabetic rats after 6, 7 and 8 weeks of treatment respectively. 
In the young ZDF diabetic rats, pioglitazone caused a complete normalization of 
plasma triglyceride levels by two weeks of treatment. In older ZDF diabetic rats, 
the effect was much more modest and plasma triglycerides were not completely 
normalized to control levels. In fact, the effect was only seen after 3 and 7 
weeks of treatment, but not at 5 weeks of treatment. This could be a result of the 
conversion from type II to type I diabetes with its relative deficiency of insulin, a 
situation known to interdict pioglitazone activity. Young hybrid diabetic rats did 
not exhibit elevated triglycerides from the start of the experiments as did the 
young and older ZDF rats. However, when the hybrid ZDF diabetic rats 
developed hypertriglyceridemia, the degree of hypertriglyceridemia was -2 .4  
fold greater than that seen in the young and older ZDF rats. This could relate to 
the additional genetic potential of developing cardiovascular abnormalities. 
Since this is the first study using the hybrid ZDF/SHHF rat model, it is difficult to
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speculate on a contribution by genetic defects. Pioglitazone, given to these 
hybrid diabetic rats, dramatically improved, but did not totally normalize, plasma 
triglyceride levels compared to untreated hybrid ZDF rats. There was no effect 
seen in control rats from this drug. Vanadyl caused a significant decrease in 
plasma triglycerides, but only after 8 weeks of treatment and at the highest 
concentration, which coincides with a significant decrease in plasma glucose.
Decreased plasma triglyceride levels are probably due to an increase in 
clearance into tissues. This has been reported in both normal and obese 
insulin resistant rats (Sugiyama et al, 1990). The increased clearance of 
triglycerides can be explained by induction of the enzyme lipoprotein lipase that 
removes triglycerides from the blood stream. Insulin resistance may decrease 
triglyceride uptake by decreasing insulin's ability to induce lipoprotein lipase 
(Ikeda et al., 1990). Another potentially important reason for decreased 
triglyceride levels is that of enhanced insulin ability to inhibit adipose tissue 
triglyceride lipase.
Free fatty acid levels were significantly elevated in the young and older ZDF 
diabetic rat groups, but not in the young hybrid diabetic rats, compared to their 
non-diabetic littermates. Drug treatment did not significantly affect these 
elevated lipid levels. Ttiis suggests that correction of hypertriglyceridemia is not 
linked to enhanced insulin inhibition of triglyceride lipase since free fatty acids 
and glycerol are the major catabolic byproducts of triglyceride metabolism. 
Interestingly, the young ZDF rats, had much lower plasma free fatty acid levels 
compared to the older ZDF and young hybrid rats. The increased free fatty acid 
levels in the older ZDF rats could be due to their hypoinsulinemic state. Insulin 
is known to stimulate lipoprotein lipase and facilitate removal of free fatty acids
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
84
from the blood stream into tissues. In the presence of little insulin, free fatty 
acids rise, potentially explaining why free fatty acid levels were higher in the 
older than in the younger rats.
Lipoprotein profiles in ZDF rats were also affected by diabetic state. Young, 
older and hybrid ZDF diabetic rats showed elevated total cholesterol levels 
compared to non-diabetic littermates. Pioglitazone treatment significantly 
reduced, but did not normalize, plasma total cholesterol levels in the young ZDF 
diabetic group while it normalized total cholesterol in the young hybrid 
ZDF/SHHF diabetic rats. Pioglitazone did not change total cholesterol levels in 
the older ZDF diabetic rats. This failure to lower total cholesterol is probably 
due to the conversion from NIDDM to IDDM during the study. HDL cholesterol 
levels were elevated in young and hybrid ZDF diabetic rats compared to non­
diabetic littermates. HDL levels in older ZDF diabetic rats appeared to be 
elevated, however a 45% standard error preclude significance. Although 
pioglitazone decreased plasma triglycerides in the young and hybrid diabetic 
rats, it did not decrease HDL levels implying that the triglycerides are derived 
from LDL and VLDL lipoproteins. There was no significant effect of pioglitazone 
in the young, old or hybrid non-diabetic rats with respect to total or HDL 
cholesterol. In KKAV mice, pioglitazone caused a 58% reduction in LDL and 
VLDL and a 25% increase in HDL cholesterol (Castle et al., 1993). It has been 
suggested that reduction in cholesterol levels may be due to a reduction in 
triglyceride levels that could produce an increase in lipoprotein lipase activity 
secondary to augmented insulin action (Sugiyama et al., 1990). Hydralazine 
had no significant effect on plasma lipoprotein profiles in older ZDF diabetic 
rats, but did significantly lower total cholestero l levels in young hybrid
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ZDF/SHHF diabetic rats and significantly elevated HDL cholesterol levels in
young hybid ZDF/SHHF diabetic rats.
Hemoglobin A1C (HbA1c) levels are a measure of glycosylated hemoglobin as 
a result of consistently elevated plasma glucose levels. It is indicative of relative 
plasma glucose control over the prolonged periods of 3 weeks or more. HbA1c 
was not measured in young ZDF rats, but was in the older and hybrid rats. In 
the older and hybrid rats a small, but significant, increase in HbA1c levels was 
observed in diabetic untreated rats compared to non-diabetic untreated rats. 
None of the drug treatments (pioglitazone, vanadyl or hydralazine) affected 
these levels in the older ZDF diabetic rats. Pioglitazone significantly decreased 
HbA1c levels in young hybrid ZDF/SHHF diabetic rats to levels seen in non­
diabetic untreated rats. This indicates that pioglitazone provided excellent 
glucose control in young NIDDM (hybrid) diabetic rats. Vanadyl had no effect 
on H b A lc  levels in e ither o lder or hybrid rats, possibly because the 
concentration of the drug was only at optimal levels for a week and would not 
significantly affect H bA lc  levels during that short period of time.
Sustained obesity is associated with cardiac hypertrophy and compromised 
ventricular function. In order to assess cardiovascular performance and overall 
cardiovascular health, we measured left ventricular developed pressure, 
maximum rate of force development (+dP/dt) and maximum rate of relaxation 
(-dP/dt) In the isolated perfused working heart apparatus using glucose as the 
sole source of energy. We also determined ventricular levels of cholesterol and 
triglycerides and observed heart weights and heart weight to body weight ratios. 
In addition, systolic, d iasto lic and mean arteria l blood pressures were
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determined in conscious restrained rats using a semi-automated tail cuff device. 
As an added component, vascular reactivity was investigated in aortic strips.
Obesity results in increased metabolic demands, one of which is for oxygen. To 
compensate for this, cardiac output increases, more specifically either stroke 
volume increases induced due to increased filling pressures (preload) (Paulson 
and Tahillani, 1992) or heart rate increases to increase cardiac output. This 
increased preload, over a period of time, results in left ventricular hypertrophy. 
In some cases, both preload and afterloads increase resulting in cardiomegaly. 
This is opposite to hypertension induced hypertrophy which results from 
increased arterial blood pressure (afterload). In obese patients, autopsy results 
indicate increased heart weights, primarily due to increased left ventricular 
mass, an increase which correlates well with increased body weight.
As a heart tries to compensate for increased filling pressures and thus becomes 
larger, there exists the possibility for ischemic episodes, myocardial infarction or 
heart failure. STZ-diabetic rats consistently show elevated heart weight to body 
weight ratios (McNeill, 1985); however, in STZ-diabetic animals, body weight is 
lower than in non-diabetic controls. To date there is no published data 
concerning heart weights in ZDF rats or hybrid ZDF/SHHF rats when exposed to 
oral hypoglycemic agents.
In our study, none of the diabetic untreated rats (young, old or hybrid) 
possessed altered heart w eights com pared to untreated non-d iabetic 
littermates. Pioglitazone, however, caused a significant increase in heart 
weights in young ZDF and young hybrid ZDF/SHHF rats with no effect on the 
older ZDF rats (IDDM). Vanadyl and hydralazine had no effect on heart weights
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in e ither diabetic or non-diabetic rats of young, old or hybrid ZDF origin. 
Hypertrophy can be beneficial initially, but if the condition progresses, it can 
lead to ventricular wall distention and weakening with the potential for 
decreased cardiac output and heart failure.
P ioglitazone did significantly increase heart weights and body weights; 
however, the degree of increase was not proportional, resulting in a significantly 
lowered heart weight to body weight ratio in the DP group compared to 
untreated young ZDF diabetic rats. There was no effect on heart weights or 
body weights caused by pioglitazone In the young non-diabetic rats or in either 
diabetic or non-diabetic older ZDF rats. Young hybrid ZDF/SHHF diabetic rats 
treated with pioglitazone also had decreased heart weight to body weight ratios 
which however, were not significant. Interestingly, hydralazine caused the non­
diabetic group to have significantly elevated heart weight to body weight ratios 
compared to untreated control rats. Normal hearts weigh approximately 4 
percent of the body weight. If the heart weight decreases compared to the body 
weight, the heart must work harder to properly perfuse the body. This can lead 
to ischemia and other cardiovascular abnormalities.
The differences seen in heart weight are interesting since the young ZDF 
diabetic rats evidenced significantly impaired cardiac performance as reflected 
by LVDP, +dP/dt and -dP/dt. In this group of rats, LVDP, +dP/dt and -dP/dt had 
reduced function at the lowest preload pressures tested. Since no blood 
pressure determinations were made in the young ZDF rats, no association 
between hypertension, hypertrophy and impaired overall cardiac performance 
at low preloads can be made. All that can be noted is that obesity can also 
cause these same effects and the DP rats were obese. This may be related to
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ischem ia in the tissues, since at low perfusion pressures, the heart is 
hypoperfused and may result in ischemia (personal communications, V. Yuen 
and S. Dai, UBC). Potentially, these DP rats may be more prone to ischemic 
episodes. To test this hypothesis, ischemia reperfusion studies would have to 
be conducted.
This phenomenon was not present in the young hybrid ZDF/SHHF diabetic 
p iog litazone treated rats which also exhibited increased heart weights. 
Pioglitazone caused a significant enhancement in LVDP of hybrid rats relative 
to diabetic untreated rats. None of the rat groups exhibited a significant 
im pairm ent of cardiovascular performance which is a well documented 
phenomenon in animal models of IDDM. There may in fact be no good model 
for cardiovascular impairment in NIDDM rats. There appeared to be a trend for 
impaired function in the young ZDF diabetic rats, but this trend was not 
observed in the older ZDF model or the hybrid model.
O lder ZDF rats were specifically chosen for the second study because we 
hypothesized that cardiomyopathy may not occur until later in the rat's life at a 
time when diabetes has significantly progressed. As it turned out, we probably 
did not use old enough rats. To compound this issue, we determined that the 
NIDDM rats slowly convert to IDDM rats, thus masking any cardiomyopathy that 
might have evolved during the phase of NIDDM. It has, however, recently been 
reported that cardiomyopathy does not occur in Zucker fatty rats until several 
months of age (Rosen et al., 1986). The greatest effect that occurred in this 
group of rats was due to hydralazine. Hydralazine significantly impaired 
diabetic -dP/dt and improved noh-diabetic -dP/dt. Hydralazine lowered blood 
pressure, but had no effect on cardiac size. It impaired rates of relaxation in
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diabetic rats, but Improved rates of relaxation In non-diabetic rats. This can not 
be related to hyperinsulinemia since It did not exist In these older ZDF rats. 
Possibly, hydralazine Interferes with electrolyte balance, ultimately affecting 
calcium levels and contractility In the heart.
Hybrid ZDF/SHHF rats not only are obese, Insulin resistant and hyperllpidemic, 
but they also have the potential to develop hypertension and/or congestive 
heart failure due to an abnormal gene expressed In the ZDF strain. It is known 
that cardiovascular complications can be potentiated by hypertension and/or 
other congenital heart defects. The possibility exists, that since this new hybrid 
strain can develop other cardiovascular abnormalities, It possibly could develop 
the "diabetic cardiomyopathy" observed In STZ-dlabetIc rats (IDDM). Since 
Impaired cardiovascular performance was not observed In either the young or 
older ZDF diabetic rats tested, this hybrid strain of rats was chosen to took for 
potential cardiomyopathy. The only effect seen In the young hybrid ZDF/SHHF 
diabetic rats was with hydralazine treatment, which significantly improved 
diabetic -dP/dt compared to non-diabetic rats.
Diabetic cardiomyopathy by definition is cardiomyopathy which occurs In the 
absence of any significant coronary artery disease. Rats typically do not 
develop coronary artery disease and thus are a good model for diabetic 
cardiomyopathy. Vanadyl, which corrects the diabetic cardiomyopathy In STZ- 
diabetic rats (Heyliger et al., 1986), had no effect In the older ZDF or hybrid 
ZDF/SHHF rats. Since significantly impaired cardiac performance was not 
observed in the diabetic rats, little Improvement could probably be expected.
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Cardiac tissue cholesterol levels, corrected for protein content were not 
Increased in young or older ZDF diabetic rat hearts compared to non-diabetic 
ra t hearts , but were s ign ifican tly  e leva ted  in the young hybrid  
ZDF/SHHFdiabetic rats. This increase in cardiac cholesterol in young hybrid 
ZDF/SHHF diabetic rats is consistent with elevated plasma cholesterol levels 
seen in this group. Pioglitazone had no effect on young, older or hybrid ZDF rat 
heart cholesterol content despite an overall increase in heart weight and a 
decrease in plasma cholesterol in diabetic groups. Hydralazine also had no 
effect on cardiac cholesterol in young or older ZDF diabetic and non-diabetic rat 
hearts, but did significantly decrease cardiac cholesterol in non-diabetic rats 
relative to both diabetic and non-diabetic untreated rats.
Elevated cardiac triglycerides have been documented in the IDDM rat model, 
the BB rat. Elevated plasma lipid concentrations can accumulate intracellularly 
where lipids might contribute to cardiac stiffness and interfere with various 
enzyme systems. Cardiac tissue triglyceride levels were elevated in young and 
older ZDF diabetic rats compared to non-diabetic littermates. Diabetic and non­
diabetic cardiac triglyceride levels in the young ZDF rats were significantly 
decreased by pioglitazone treatment. This could be due to a secondary effect of 
pioglitazone to decrease circulating plasma triglyceride levels. It could, 
however, be a direct effect of the drug to stimulate lipoprotein lipase in the 
cardiac tissue. Vanadyl normalized elevated cardiac triglyceride levels in the 
older diabetic rats, but had no effect in non-diabetic rats. Pioglitazone had no 
effect on this cardiac parameter in older ZDF diabetic rats. Once again this is 
probably due to the IDDM state. Although hydralazine reduced plasma 
triglycerides significantly after 7 weeks of treatment, it significantly increased the 
cardiac triglyceride levels of older ZDF diabetic rats. Perhaps this is because
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plasma triglycerides are being removed and subsequently deposited in tissues 
such as the heart. Another possibility is that there is abnormal fatty acid 
metabolism, such as reduced amounts of carnitine involved in mitochondrial 
uptake of free fatty acids. Levels of cardiac triglycerides in the young hybrid 
ZDF/SHHF diabetic rats are not significantly different from the levels in non­
diabetic rats. Pioglitazone, hydralazine and vanadyl had no effect in either 
d iabetic or non-diabetic rats of hybrid origin. The amount of cardiac 
triglycerides is lower in the young hybrid rats compared to the older ZDF rats 
and the higher levels in older rats may be reflective of their IDDM where 
elevated triglyceride levels have been previously noted.
Decreasing cardiac lipids is important for diabetics. In contrast to non-diabetics, 
diabetic individuals tend to use more free fatty acids than glucose to function 
normally. If triglyceride levels are high, free fatty acid levels increase as 
triglyceride lipase breaks down triglycerides. Another potential problem with 
elevated cardiac lipids is coronary artery disease or hypertension, two important 
problems associated with diabetic populations. This suggests that any drug 
capable of decreasing both plasma and cardiac tissue lipids would be an 
added benefit to NIDDM patients. This is the case with pioglitazone in young 
ZDF diabetic rats and hydralazine in older ZDF diabetic rats.
Hypertension has been associated w ith hyperinsulinem ia and insulin 
resistance in human subjects with essential hypertension and in various animal 
m odels of hypertension including spontaneously hypertensive (SH) rats. 
Several recent studies investigating the relationship between hyperinsulinemia 
and hypertension have indicated that hyperinsulinemia may contribute to the 
development of hypertension in SH rats. In separate studies, vanadyl sulfate
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and b is (m a lto la to )oxovanad ium (lV ) (an organ ic vanadium  com plex) 
concomitantly decreased plasma insulin and blood pressure (Bhanot, S., et al, 
Hypertension, in press; Bhanot, S., et al, 1994). Vanadyl sulfate has also been 
shown to prevent fructose-induced hyperinsulinemia and hypertension in rats 
(Bhanot, S., et al., 1993).
CS-045, another thiazolidinedione, has also been observed to have concurrent 
insulin and blood pressure lowering effects in 7 month old obese Zucker rats 
(Yoshioka et al., 1993). Since these rats were not hyperglycemic, it rules out 
the possibility that hyperglycemia caused the hypertension. In a study using 
pioglitazone in Insulin resistant rhesus monkeys, the drug decreased insulin, 
glucose, triglycerides and blood pressure, indicating an association between 
insulin resistance and hypertension in these animals (Kemnitz, J.W., et al., 
1994). It has recently been suggested that the hypotensive activity of 
pioglitazone is not always associated with normal insulin sensitivity (Zhang, 
H.Y., et al., 1994). These authors suggest that pioglitazone's ability to decrease 
peripheral resistance in Dhal salt rats (insulin resistant) may be due to inhibited 
growth of vascular smooth muscle cells as a result of alterations in intracellular 
calcium. A study, investigating the relationship between intracellular calcium 
and hypertension in obese rats, determined that decreased insulin and blood 
pressure correlated with a significantly decreased capacity of platelet-derived 
growth factor BB homodimer to induce sustained increases in intracellular free 
calcium (Pershadsingh, H.A., et al, 1993). This study suggests that a novel 
pharmacological approach to the treatment of hypertension might be to modify 
cell calcium responses to pressor agents, growth factors, or both.
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Systolic, diastolic and mean arterial blood pressures were not determined in the 
young ZDF rats. Older ZDF diabetic rats did not exhibit any hypertension 
compared to non-diabetic rats. The absolute value of systolic and diastolic 
blood pressures in both diabetic and non-diabetic rats is m ildly elevated 
compared to what has been reported for non-obese rats. This agrees with 
stud ies in Zucker rats which indicate that s ign ificant card iovascu lar 
abnormalities do not occur until several months of age. Although we named 
these ZDF rats older, they are only 5 months old at the end of the experiment.
In the young hybrid ZDF/SHHF rats, hydralazine significantly decreased 
systolic, diastolic and mean arterial blood pressures in both diabetic and non­
diabetic rat groups compared with untreated littermates. Hydralazine is known 
to be a direct arterial vasodilator; moreover, hydralazine caused a concomitant 
decrease in plasma triglyceride levels in the diabetic rats. This triglyceride 
lowering effect was also seen by Rodrigues et al., (1986) in STZ-diabetic rats 
and occurred concurrently with decreased systolic blood pressure and 
improved cardiac performance. Our results do not indicate improved cardiac 
performance in the diabetic rats, but do suggest improved cardiac performance 
in non-diabetic rats. Hydralazine increased the rate of relaxation without 
changing the rate of force development or left ventricular developed pressure. 
Young hybrid ZDF/SHHF diabetic rats had similar systolic and mean arterial 
blood pressures to the older ZDF rats, but had lower diastolic blood pressures. 
As in the older ZDF rats, there was no difference in blood pressure between 
diabetic and non-diabetic rats. In this study, hydralazine tended to cause a 
decrease in blood pressure (-9 %  decrease in systolic; -10%  decrease in 
d iastolic; -12%  decrease in mean arterial blood pressure in diabetic rats) 
which, however, did not attain significance. In this study, p ioglitazone
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significantly reduced the systolic (10%), diastolic (11%) and mean arterial 
(12%) blood pressures of diabetic rats compared to control untreated rats. This 
effect occurred concomitantly with decreased plasma glucose, triglycerides, 
cholesterol and insulin. Several of these parameters could have contributed to 
the  hypo tens ive  e ffec ts  of p iog litazone. However, co rrec ting  the 
hyperinsulinemia present in these rats may play a significant role since no effect 
was seen in our older, insulin deficient, ZDF rats (IDDM).
Some members of the research community have expressed concern about the 
reliability of non-invasive, tail cuff blood pressure determinations. There are 
several reasons to believe the validity of our readings. First, the rats were 
acclimated to the surroundings on several occasions to establish baseline 
responses before their determinations. Second, the rats were housed in 
temperature controlled conditions. Third, there are several papers which have 
determined that there is no significant difference between invasive and non- 
invasive blood pressure readings (Bhanot, S., et al., 1994). Fourth, we 
observed an expected decrease in blood pressure upon treatment with a direct 
vasodilator, hydralazine.
Vascular reactivity is a measure of the sensitivity of vascular tissue, such as 
aortas, to certain pharmacological agents, such as norepinephrine. Many 
studies have been conducted to evaluate vascular sensitivity and reactivity. 
Results of these studies show increased, decreased or no change in vascular 
reactivity, depending on the experimental conditions and animal model used. 
To date, there is very little evidence that there is any change in NIDDM rats. It is 
believed that increased sensitivity may be associated with hypertension.
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O lder ZDF diabetic rats had significantly h igher maximum responses to 
norepinephrine than did non-diabetic littermates. As this group of rats closely 
resembles IDDM, this is consistent with previously published results (Gattu, M., 
1993). Pioglitazone decreased aortic sensitivity in the older ZDF diabetic rats, 
but had no effect on non-diabetic littermates. The effects of pioglitazone in this 
instance are probably not a direct effect of the drug since these rats were 
hypoinsulinemic and insulin is necessary for pioglitazone to exert its effects. In 
these rats, there was no effect of the drug on blood pressure, so this Improved 
vascular characteristic can not be entirely responsible for changes in blood 
pressure. Likewise, vanadyl sulfate improved vascular sensitivity in older ZDF 
diabetic rats with no effect on non-diabetic rats and no corresponding effects on 
blood pressure. Hydralazine, on the other hand, had no effect on diabetic rats, 
but significantly increased sensitivity in non-diabetic rats. Hydralazine also had 
a concomitant blood pressure lowering effect in both diabetic and non-diabetic 
rats. This does not agree with the theory that increased vascular sensitivity 
results in hypertension. Maximum vasoconstriction to the depolarizing agent, 
KCl (40 mM), in these older ZDF diabetic rats was also significantly greater than 
non-diabetic littermates. This is opposite to the decreased effect in IDDM 
reported by Gattu (1993) and Fulton (1991). Possibly this is because these rats 
had not been insulin dependent for a significant period of time as they belatedly 
converted from NIDDM to IDDM. Pioglitazone and vanadyl decreased 
vasoreactiv ity in d iabetic rats while hydralazine increased non-diabetic 
responsiveness.
In the young hybrid ZDF/SHHF diabetic rats, a significant difference was not 
observed in vascular sensitivity compared with non-diabetic rats. Pioglitazone, 
vanadyl and hydralazine also had no effect on vascular sensitivity in this model
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of NIDDM. This agrees with previous results in young ZDF diabetic rats (Gattu, 
M., 1993). Since there was a significant blood pressure lowering effect seen 
with pioglitazone treatment in these hyperinsulinémie rats, but no effect on 
vascular sensitivity, hypertension could be produced from some means other 
than vascular impairment. It is probably more likely that hyperinsulinemia or 
insulin resistance is responsible for, and certainly associated with, hypertension 
in young hybrid ZDF/SHHF rats. Maximum response to 40 mM KCl was also 
not affected by either disease or drug therapy. This is in agreement with the 
results of Gattu (1993), who observed similar results in young ZDF diabetic rats.
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5 .0  C O N C L U S IO N S
Pioglitazone reduced hyperglycemia, hyperlipidemia and hyperinsulinem ia 
e ffective ly at a dose an oral dose of 10 mg/kg/d ay when adm inistered 
ch ro n ica lly  to young ZDF and young hybrid  ZDF/SH H F d iabe tic  
hyperinsulinémie rats. The reduction of plasma glucose in hyperinsulinémie but 
not hypoinsulinemic NIDDM rats indicates that pioglitazone's mechanism of 
action involves reversal of insulin resistance. The reduction of plasma 
cholesterol levels by pioglitazone appears to be associated with decreased 
LDL since HDL levels were not affected, and plasma triglyceridses were 
dramatically reduced. Pioglitazone promotes a potentially detrimental gain in 
body weight in ZDF and hybrid ZDF/SHHF NIDDM rats. It was evident that 
pioglitazone impaired maximum left ventricular pressure and rates of force 
development and relaxation in young ZDF diabetic rats relative to non-diabetic 
untreated rats at the lowest filling pressures and improved maximum left 
ventricular developed pressure in non-diabetic rats relative to untreated non­
diabetic rats. Pioglitazone caused increased heart weights and body weights in 
both young and hybrid ZDF diabetic rats and potentially decreased heart weight 
to body weight ratios (seen in young ZDF diabetic rats, but not hybrid 
ZDF/SHHF diabetic rats). Pioglitazone, however, significantly lowered blood 
pressure in the young diabetic hybrid ZDF/SHHF rats relative to their non­
diabetic littermates at a time when the untreated diabetic animals had blood 
pressures that approximated those of control littermates. Since pioglitazone 
lowered blood pressure in diabetic hybrid ZDF/SHHF rats, but not in their 
control littermates, the implication is that pioglitazone lowers blood pressure by 
its ab ility  to  correct hyperinsulinem ia by re-establishing normal insulin 
sensitivity.
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Vanadyl sulfate (0.75 mg/ml), administered orally In drinking water, improved 
hyperglycemia in older ZDF diabetic rats as a concomitant body weight loss 
occurred. It improved but did not normalize the hyperglycem ia and 
hypertriglyceridemia of hybrid ZDF/SHHF diabetic rats without changing body 
weights. This suggests that vanadyl's mechanism of action Is distinctly different 
from the mechanism of pioglitazone to reduce plasma glucose and lipids.
Hydralazine (5 mg/kg b.i.d.), administered orally, effectively decreased plasma 
cholesterol in hybrid ZDF/SHHF diabetic rats and plasma triglycerides in older 
ZDF diabetic rats. Hydralazine improved the rates of relaxation in non-diabetic 
o lder ZDF rats by improving rates of relaxation, in contrast, hydralazine 
impaired rates of relaxation in older ZDF diabetic rats at the higher preloads. 
However, in the hybrid ZDF/SHHF rats indicated that diabetic rats treated with 
hydralazine improved relative to non-diabetic rats with respect to rates of 
relaxation. There were no changes in cardiac cholesterol levels in the two 
NIDDM rat groups (young ZDF and hybrid ZDF/SHHF) while cardiac 
triglycerides decreased in young hybrid ZDF/SHHF diabetic rats treated with 
hydralazine compared to non-diabetic rats. Hydralazine significantly reduced 
blood pressure in the older ZDF rats and tended to lower blood pressures in the 
young hybrid ZDF/SHHF rats. The mechanism of action of hydralazine to 
reduce blood pressure is through direct vasodilation, which is obviously 
distinctly different from the mechanism by which of pioglitazone reduces blood 
pressure.
Evaluation of the cardiovascular param eters measured in these studies 
indicated that neither young, old or hybrid ZDF diabetic rats are a good model to
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study diabetic cardiovascular abnormalities that manifest them selves as 
impaired cardiac performance or increased vascular reactivity. Since no 
im paired cardiovascular impairment occurred with respect to these two 
param eters in diabetic rats, it is premature to speculate on the potential 
beneficial or detrimental effects of pioglitazone, vanadyl or hydralazine. Thus, 
the NIDDM rat models used in the present study were not useful for determining 
cardiovascular abnormalities associated with diabetes in the isolated perfused 
working heart apparatus during the time frame tested.
In addition to the aforementioned results, systolic, diastolic and mean arterial 
blood pressures were not elevated in the insulin resistant NIDDM diabetic rats 
relative to non-diabetic littermates in the hybrid ZDF/SHHF model. Data 
suggest that the blood pressures in this genetic rat model are higher than 
normal regardless of diabetic status. Thus, none of these NIDDM rat models 
appear to be good models in which to study hypertension related to insulin 
resistance in NIDDM, and it can be speculated that hyperinsulinemia especially 
if short term is not predictive of an ensuing elevation of blood pressure.
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